



# An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease

Sally J. Singh, Milo A. Puhan, Vasileios Andrianopoulos, Nidia A. Hernandez, Katy E. Mitchell, Catherine J. Hill, Annemarie L. Lee, Carlos Augusto Camillo, Thierry Troosters, Martijn A. Spruit, Brian W. Carlin, Jack Wanger, Véronique Pepin, Didier Saey, Fabio Pitta, David A. Kaminsky, Meredith C. McCormack, Neil MacIntyre, Bruce H. Culver, Frank C. Sciruba, Susan M. Revill, Veronica Delafosse and Anne E. Holland

**Affiliations:** For a full list of the authors' affiliations please refer to the Acknowledgements.

**Correspondence:** Sally J. Singh, Centre for Exercise and Rehabilitation Science, University Hospitals of Leicester NHS Trust, Groby Road, Leicester, LE3 9QP, UK. E-mail: [sally.singh@uhl-tr.nhs.uk](mailto:sally.singh@uhl-tr.nhs.uk)

**ABSTRACT** This systematic review examined the measurement properties of the 6-min walk test (6MWT), incremental shuttle walk test (ISWT) and endurance shuttle walk test (ESWT) in adults with chronic respiratory disease.

Studies that report the evaluation or use of the 6MWT, ISWT or ESWT were included. We searched electronic databases for studies published between January 2000 and September 2013.

The 6-min walking distance (6MWD) is a reliable measure (intra-class correlation coefficients ranged from 0.82 to 0.99 in seven studies). There is a learning effect, with greater distance walked on the second test (pooled mean improvement of 26 m in 13 studies). Reliability was similar for ISWT and ESWT, with a learning effect also evident for ISWT (pooled mean improvement of 20 m in six studies). The 6MWD correlates more strongly with peak work capacity ( $r=0.59-0.93$ ) and physical activity ( $r=0.40-0.85$ ) than with respiratory function ( $r=0.10-0.59$ ). Methodological factors affecting 6MWD include track length, encouragement, supplemental oxygen and walking aids. Supplemental oxygen also affects ISWT and ESWT performance. Responsiveness was moderate to high for all tests, with greater responsiveness to interventions that included exercise training.

The findings of this review demonstrate that the 6MWT, ISWT and ESWT are robust tests of functional exercise capacity in adults with chronic respiratory disease.



@ERSpublications

Systematic review: support for use of the 6MWT, ISWT and ESWT in adults with chronic respiratory disease <http://ow.ly/Bq2Mz>

---

This article has supplementary material available from [erj.ersjournals.com](http://erj.ersjournals.com)

Received: Aug 17 2014 | Accepted: Aug 31 2014 | First published online: Oct 30 2014

**Support statement:** The realisation of this systematic review would not have been possible without the financial support of the European Respiratory Society and American Thoracic Society. Sally J. Singh is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care East Midlands (CLAHRC EM), and work took place at the University Hospitals of Leicester NHS Trust. Support was also provided by the NIHR Leicester Respiratory Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Dept of Health.

**Conflict of interest:** Disclosures can be found alongside the online version of this article at [erj.ersjournals.com](http://erj.ersjournals.com)

Copyright ©ERS 2014

## Overview

The aim of this systematic review was to examine the measurement properties for the 6-min walk test (6MWT), incremental shuttle walk test (ISWT) and endurance shuttle walk test (ESWT) in adults with chronic respiratory disease. A companion paper describes the standard operating procedures for the tests [1]. The key findings of this systematic review are as follows.

- 1) The 6-min walking distance (6MWD) is a valid and reliable measure of exercise capacity for people with chronic lung disease. The 6MWD correlates more strongly with measures of peak work capacity and physical activity than with respiratory function or quality of life, which supports its conceptualisation as a test of functional exercise performance.
- 2) The ISWT offers a different protocol to the 6MWT as it is incremental and externally paced. The ISWT is a valid and reliable measure of cardiopulmonary exercise capacity in chronic obstructive pulmonary disease (COPD), where there is a strong relationship between ISWT distance and peak oxygen uptake ( $V'O_{2peak}$ ) or work rate on a cardiopulmonary exercise test (CPET).
- 3) A learning effect is observed for the 6MWT and the ISWT. The second test usually is the better compared with the first, but this is inconsistent.
- 4) The ESWT is a test of endurance capacity. It is externally paced and is performed along the same course as the ISWT. Two tests do not appear to be necessary if the second test is conducted on the same day.
- 5) Reference equations have been proposed for the 6MWD and the ISWT. Age, height and weight are included in most equations. The influence of race and ethnicity is unclear.
- 6) The safety profile of the 6MWT, ISWT and ESWT is good, with few significant adverse events reported in people with chronic respiratory disease.
- 7) Performance on the 6MWT can be influenced by the course layout and track length. Such variations have not been reported for the ISWT or the ESWT.
- 8) Walking aids used during the 6MWT can improve walking distance; those with greater levels of disability appear to gain the most.
- 9) Supplemental oxygen increases the distance walked on the 6MWT, ISWT and ESWT. The difference is greatest when the cylinder is not carried by the patient.
- 10) There is a strong association between shorter 6MWD and an increased risk of mortality for patients with COPD, interstitial lung disease (ILD), pulmonary hypertension and those awaiting transplantation. Similar observations are made for the ISWT (mainly for COPD), but there are fewer data in comparison with the 6MWT.
- 11) The primary outcome measure for the 6MWT and ISWT is distance walked, recorded in metres or feet. The ESWT is usually reported as time.
- 12) The minimal important difference (MID) for 6MWD in adults with chronic respiratory disease lies between 25 and 33 m. A change of 47.5 m (approximately five shuttles) is reported to be clinically important for the ISWT. The MID for the ESWT is reported as 65 s or 85 m after bronchodilation. A MID for the ESWT after rehabilitation has yet to be confirmed.
- 13) The 6MWD, ISWT and the ESWT are sensitive to change, particularly after a course of rehabilitation.

## Background

Field walking tests play a key role in evaluating functional exercise capacity, assessing prognosis, determining outcome of clinical trials and evaluating response to treatment across a wide range of chronic respiratory diseases. Since the previous American Thoracic Society (ATS) statement on the 6MWT was published in 2002 [2], new information regarding field walking tests has been reported in a range of key areas. This includes the emergence of the ISWT and ESWT as frequently used tests of exercise performance in people with chronic respiratory disease. There is also a new body of knowledge relevant to the good conduct and utility of the 6MWT in both research and clinical settings. This growth in knowledge provides an opportunity to update the standards for field test performance, to enhance test quality and interpretation.

The overall aim of this systematic review was to inform the development of technical standards for the 6MWT, ISWT and ESWT in adults with chronic respiratory disease. The Technical Standard has been published separately [1]. The specific questions addressed in this review were as follows. 1) Are the 6MWT, ISWT and ESWT reliable and valid tests of exercise capacity in people with chronic respiratory disease? 2) Which methodological factors affect test performance in adults with chronic respiratory disease? 3) What

is the relationship of 6MWT, ISWT or ESWT performance to clinical outcomes in people with chronic respiratory disease? 4) Which test parameters, apart from distance, should be reported in people with chronic respiratory disease? 5) What kind of monitoring is required during the 6MWT, ISWT and ESWT in people with chronic respiratory disease? 6) Which reference equations can be used for the 6MWT, ISWT and ESWT? 7) Can the 6MWT, ISWT and ESWT identify clinically meaningful change in people with chronic respiratory disease?

## Methods

An *ad hoc* Task Force was assembled to develop technical standards for the performance of the 6MWT, ISWT, and ESWT based upon a systematic review of the evidence. Co-chairs were selected by the Pulmonary Rehabilitation Assembly and Proficiency Standards Committee of the ATS and the Rehabilitation and Chronic Care Assembly and Allied Respiratory Professionals Assembly of the European Respiratory Society (ERS), then approved by the leadership of both societies. Members of the Task Force were selected by the co-chairs on the basis of their expertise in application of field walking tests in research and/or clinical practice. All potential conflicts of interest were disclosed and managed according to the policies and procedures for joint ATS/ERS projects.

### Inclusion criteria

Studies that reported the evaluation or use of the 6MWT, ISWT or ESWT in adults with chronic respiratory disease were included. There were no restrictions on study design. Review papers were not included except in question 7, to determine responsiveness of field tests to interventions. Studies published in any language were included, provided an English abstract was available. Translations of the full text were obtained where necessary. Studies included adults with chronic respiratory disease of any type, diagnosed according to the investigators' definition. Paediatric studies were not included. As the performance, predictive value and measurement properties of the field tests may vary according to population, analyses were conducted separately for each disease group. Some review questions had additional, specific inclusion criteria and outcomes of interest, which are detailed in the online supplementary material.

### Search methods

EMBASE, MEDLINE, CINAHL, PEDro and the Cochrane Library were initially searched for articles published between the year 2000 and May 10, 2012; the search was then updated in September 2013. The search strategies can be found in the online supplementary material. Reference lists of all primary studies and review articles were checked for additional references. Selected studies published before 2000 were included where necessary.

### Selection of studies

Two reviewers excluded studies that clearly did not meet the inclusion criteria based on title or abstract. Studies that met the inclusion criteria, or studies where it was not possible to determine inclusion based on title and abstract, were retrieved in full text to determine their inclusion. Full text papers were reviewed independently by two reviewers to determine whether they were suitable for inclusion. Disagreements were resolved by consensus or a third reviewer where required.

Data were extracted by two reviewers independently. Differences were resolved by consensus or a third reviewer where required. Where possible, a pooled estimate of effect was calculated. Where it was not possible to combine data, a narrative synthesis was performed.

## Results

### 6MWT

The 6MWT is a self-paced test of walking capacity. Patients are asked to walk as far as possible in 6 min along a flat course. Walking distance is the primary outcome and is recorded in metres or feet. Standardised instructions and encouragement are commonly given during the test [2].

The initial search returned a total of 2990 records, after removal of duplicates. After removal of records that were not related to the 6MWT or adults with respiratory disease, 1392 records remained. The updated search in September 2013 returned a total of 520 records, of which 161 were pertinent to the 6MWT or individuals with chronic respiratory disease. Further details on selection of studies for each section are given in the online supplementary material.

### Reliability of the 6MWD

Reliability is the extent to which a test provides the same result on repeated testing occasions. 30 studies were included in this section: 19 studies in COPD, six studies in cystic fibrosis (CF), six studies in ILD

(of which two were also included in the COPD section) and one study in pulmonary arterial hypertension (PAH). Characteristics of the included studies are given in the online supplementary material (tables S1, S4 and S6).

The 6MWD is a reliable measure, with intra-class correlation coefficients (ICCs) ranging from 0.72 to 0.99 (seven studies) (table S2) [3–8]. Coefficients of variation were small, with narrow ranges in COPD (0.0475–0.073) [3, 9–11], ILD (0.042–0.083) [11–13] and CF (0.0409–0.043) [14, 15]. There were no discernible differences in reliability across diagnostic groups. These data indicate that the vast majority of variation in the 6MWD can be attributed to between-patient variation, rather than within-patient variation. However, the limits of agreement were large (table 1). These studies showed that, although the 6MWD is a reliable measurement, the results of the second test cannot be predicted from the first test.

#### Learning effect on 6MWD

There is strong evidence of a learning effect for the 6MWD when two or more tests are conducted. 13 studies in patients with COPD showed a pooled mean improvement on the second 6MWT of 26.3 m (table 1). This estimate did not change when including only the subgroup of studies where the two tests were conducted within 24 h (26.1 m). The largest study to address this issue (n=1514) reported a 95% confidence interval for the learning effect of 24–29 m [8]. We can be confident that the mean learning effect on the second 6MWT lies within this range and additional data are unlikely to change this conclusion. Fewer data were available in other chronic respiratory diseases (tables S5 and S7) [11, 13–15, 23–26].

In COPD, the proportion of individuals who walked further on the second 6MWT ranged from 50% to 87% (table S3) [6, 8, 13, 22]. The proportion of individuals who had a clinically significant improvement in 6MWD on their second walk ranged from 15% for an improvement of >54 m [6] to 28% for an improvement of  $\geq 42$  m [8]. In ILD, one study reported that 86% of participants increased their 6MWD on the second test [13].

#### Effects of test repetition and familiarity on 6MWD

The learning effect appears to be moderated by test repetition and practice, at least in the short term. Three studies in COPD reported that there was a statistically significant increase in walk distance between walks 1 and 3 on a single day [4, 7, 10]. However, one study reported no significant difference between 6MWD for walks 2 and 3 (mean increase 3 m). After three walks, further repetition did not consistently improve 6MWD [4, 10]. In patients with COPD who had performed the 6MWT twice prior to rehabilitation, the post-rehabilitation difference was smaller, although the learning effect may have returned by 3 months (table S3) [22].

TABLE 1 Difference in distance between repeated 6-min walk tests in chronic obstructive pulmonary disease

First author [ref.]	Subjects n	Timepoint	Mean difference (95% CI) m	Limits of agreement m	Mean difference (95% CI) as % of baseline
LEACH [4]	30	Same day			17.1 (14–20)
POULAIN [16]	10	6 days	-5		
REJESKI [17]	30	1 week	22		4.6
RODRIGUES [18]	35	1 day	35		
ROOMI [19]	15	2–10 days	0.65 (-15.3–16.6)	-62–64	
STEVENS [20]	21	Same day	33		
TROOSTERS [21]	20	NA	15 (2.3–27.7)		2.6
IRIBERRI [10]	30	3 days	55		10.0
SCIURBA [6]	470	1 day	20.1 (16.1–24.1)	-60–107	7.0
EISER [7]	23	Same day	11		
SPENCER [22]	44	Same day	27 (12–42)	-71–148	
JENKINS [13]	245	Same day	37 (33–41)		11.0 (9–12)
KOZU [11]	45	1 day	13		
HERNANDES [8]	1514	1 day	27 (24–29)	-60–120	7.0
<b>Pooled mean</b>			26.3		6.9

NA: not available.

*Reliability of other measures taken during the 6MWT*

## Oxyhaemoglobin saturation measured with pulse oximetry

Nine studies in COPD, ILD and CF reported the reliability of arterial oxygen saturation measured by pulse oximetry ( $S_{pO_2}$ ) measures during the 6MWT (table S8). Mean differences were generally small (1–2%) (table S8) [15, 18, 22, 24]. In COPD and CF, the ICCs for  $S_{pO_2}$  ranged from 0.81 to 0.97 [8, 15, 27]. However, in systemic sclerosis-associated ILD (SSc-ILD), the ICCs ranged from 0.24 to 0.64, with the most reliable measures obtained using forehead oximetry [24]. This may reflect the difficulty in achieving reliable  $S_{pO_2}$  measures in this population due to underlying vascular disease. Another study in people with ILD, most of whom had idiopathic pulmonary fibrosis (IPF), also showed substantial measurement variation, with a coefficient of variation of 0.283 [12]. Kappa values for detecting desaturation ( $S_{pO_2} \leq 88\%$  or fall  $\geq 4\%$ ) were variable, ranging from 0.52 to 0.93 [28].

## Heart rate

Six studies in COPD and CF reported the reliability of heart rate (HR) measures (peak HR or change from rest) during the 6MWT (table S9) [8, 15, 16, 18, 22, 27]. Mean differences between tests ranged from -4 bpm to +8 bpm. The ICCs ranged from 0.28 to 0.87 and coefficients of variation ranged from 0.04 to 0.11. There were no clear differences according to underlying disease.

## Symptom scores

10 studies in COPD, ILD and CF reported the reliability of symptom scores during the 6MWT (table S10) [7, 8, 12, 15, 16, 18, 22–24, 27].

## Dyspnoea

Eight studies reported on reliability of the modified Borg dyspnoea scale [29], with ICCs from 0.59 to 0.92 and mean differences of <1 point. The modified Borg dyspnoea scale may be more reliable than the 15-count dyspnoea scale (ICC 0.66) [27] and visual analogue scale for dyspnoea (coefficient of variation 0.22) [16]; however, few studies have investigated these measures (table S10).

## Fatigue

Three studies reported the reliability of the Borg fatigue scale. One study reported an ICC of 0.59 [8]. Another reported a kappa of 0.52 for post-6MWT fatigue, compared with 0.71 for post-6MWT dyspnoea (table S10) [15].

*Validity of the 6MWD*

Validity is the extent to which a test measures the concept that it is intended to measure. 68 studies were included in this section: 34 studies in COPD; 12 studies in ILD, one of which is also included in the COPD section; seven studies in SSc, one of which is also included in the ILD section; three studies in CF; eight studies in PAH, one of which is also included in the SSc section and one in the ILD section; and eight studies in other disease groups. Full details of included studies are given in the online supplementary material (tables S11–S15).

## Relationship of 6MWD to measures of peak exercise capacity

The relationship between 6MWD and  $V'_{O_{2peak}}$  on a progressive incremental CPET was moderate to strong, with correlation coefficients ranging from 0.4 to 0.8 (table 2). This relationship was consistent across patient groups. The correlation coefficients for the relationship between 6MWD and peak work on CPET ranged from 0.58 to 0.93 with no difference across patient groups (table 2).

## Is the 6MWT a maximal test?

A comparison of peak cardiorespiratory responses on the 6MWT and CPET has been made in 10 studies in COPD, ILD and PAH (table 3). These studies generally included people with moderate to severe lung disease (e.g. in COPD studies, average forced expiratory volume in 1 s (FEV<sub>1</sub>) ranged from 37% to 52% predicted) and with moderately impaired functional exercise capacity (average 6MWD ranged from 403 to 539 m). The studies excluded people requiring supplemental oxygen or gait aids, due to the nature of the testing protocols. There was no difference between tests in  $V'_{O_{2peak}}$  or peak HR for seven out of the eight studies where these were reported. However, the peak carbon dioxide production ( $V'_{CO_{2peak}}$ ), peak ventilation ( $V'_{Epeak}$ ) and respiratory exchange ratio were significantly lower during the 6MWD in six out of the seven studies where these variables were measured. There were no discernible differences between patient groups.

TABLE 2 Relationship between 6-min walking distance and peak oxygen uptake ( $V'O_{2peak}$ ) or peak work in chronic respiratory disease

First author [ref.]	Diagnosis	Subjects n	$V'O_{2peak}$		Peak work	
			Pearson's r	Spearman's rho	Pearson's r	Spearman's rho
WIJKSTRA [30]	COPD	40			0.81	
REJESKI [17]	COPD	209	0.64			
CHUANG [31]	COPD	27	0.40			
OGA [32]	COPD	36		0.64		0.64
CARTER [33]	COPD	124	0.54		0.59	
SATAKE [34]	COPD	12			0.64	
TURNER [35]	COPD	20	0.73		0.83	
STAROBIN [36]	COPD	50	0.58			
HILL [37]	COPD	50	0.63		0.75	
LUXTON [38]	COPD	22			0.63	
DÍAZ [39]	COPD	81	0.78			
KOZU [11]	COPD	45	0.80		0.80	
SILLEN [40]	COPD	2906	0.67			
EATON [12]	IPF	29		0.78		
KOZU [11]	IPF	35			0.80	
HOLLAND [41]	ILD	14			0.93	
DALE [42]	Asbestos-related pleural disease	25	0.53		0.58	
MIYAMOTO [43]	PAH	27	0.70			
DEBOECK [44]	PAH	20	0.48			
FOWLER [45]	EIPAH	17	0.72			
BALDI [46]	LAM	40	0.55			
CAHALIN [5]	End-stage lung disease, pre transplant	30	0.73			
ROSS [47]	Mixed chronic lung diseases, many pre transplant	48	0.59			

COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; EIPAH: exercise-induced PAH; LAM: lymphangioleiomyomatosis.

#### Relationship of 6MWD to disease severity

There were weak to moderate correlations between 6MWD and measures of disease severity such as FEV<sub>1</sub> (in COPD; correlation coefficients 0.31–0.70) (table S16) [17, 30–32, 50–58], forced vital capacity (FVC) or diffusing capacity of the lung for carbon monoxide (DLCO) (in ILD and SSc; correlation coefficients 0.06–0.61) (tables S17 and S18) [12, 23, 59–65]. In COPD, two studies reported that the relationship between FEV<sub>1</sub> and 6MWD was stronger in more severe disease [54, 66]. In CF, one study reported moderate relationships between 6MWD and FEV<sub>1</sub> (r=0.53) and FVC (r=0.62) [67]. In PAH, correlations between 6MWD and mean pulmonary artery pressure ranged from -0.2 to -0.62 [43, 63, 68, 69].

#### Relationship of 6MWD to patient-reported outcomes

Although the 6MWD was consistently associated with symptoms and health-related quality of life (HRQoL) across all disease groups, these relationships were generally of weak to moderate strength (correlation coefficients 0.01–0.65) (tables S19 and S20) [17, 19, 30, 32, 42, 50, 51, 56, 58, 61, 62, 67, 70, 71].

#### Relationship of 6MWD to physical activity

There were moderate to strong relationships between 6MWD and objective measures of physical activity in patients with COPD, CF, ILD and PAH (correlation coefficients 0.38–0.85) (table 4).

#### Multivariate models for predicting 6MWD

A wide variety of independent predictors of 6MWD were identified, with no consistency within or between disease groups (tables S21 and S22) [19, 30, 32, 50, 51, 58, 60, 64, 82]. These models predicted between 20% and 70% of the variation in 6MWD, suggesting that there are other contributors to 6MWD that have not yet been defined.

TABLE 3 Comparison of physiological responses to the 6-min walk test ( $\delta$ MWT) and cardiopulmonary exercise test (CPET)<sup>#</sup>

First author [ref.]	Subjects n	Patient group	$V_{O_2,peak}$ mL·min <sup>-1</sup>		HR peak bpm		$V_{CO_2,peak}$ mL·min <sup>-1</sup>		RER		$V_{E,peak}$ L·min <sup>-1</sup>	
			$\delta$ MWT	CPET	$\delta$ MWT	CPET	$\delta$ MWT	CPET	$\delta$ MWT	CPET	$\delta$ MWT	CPET
TROSTERS [21]	20	COPD	1400±290	1410±180	126±13	130±13	1300±310	1450±180*	0.92±0.07	1.04±0.08*	42±8	47±8*
SATAKE [34]	12	COPD	14.5±2.1 <sup>†</sup>	13.9±3.6 <sup>†</sup>	109±19	112±16	12.56±2.02 <sup>†</sup>	14.55±5.45 <sup>†</sup>			26±7	29±11
TURNER [35]	20	COPD			126±15	124±12						
LUXTON [38]	22	COPD	1394±404	1383±437	121±9	128±22	1069±378	1208±434*			44±13	48±15*
HILL [37]	50	COPD			119±15	123±17						
HILL [48]	26	COPD	1168±344	1186±314	128±17	128±19	1009±270	1173±350*	0.87±0.11	0.99±0.17*	41±17	48±17*
BLANCO [49]	13	ILD	14±2 <sup>†</sup>	15±2 <sup>†</sup>	112±19	125±2*			0.94±0.1	1.02±0.07*	46.4±15.1	53.8±14.6*
HOLLAND [41]	14	ILD	15.1±3.5 <sup>†</sup>	17.5±2.6 <sup>†,*</sup>								
DEBOECK [44]	20	PAH	14.2±2.7 <sup>†</sup>	12.9±3.1 <sup>†</sup>	119±17.9	135±17.9	881±290	1024±380 <sup>†,*</sup>	0.90±0.09	1.15±0.09*	46.0±14.8	53.6±17.4*
BLANCO [49]	14	PAH	16±6 <sup>†</sup>	16±6 <sup>†</sup>	142±24	146±23			1.00±0.12	1.17±0.08 <sup>†,*</sup>	52.2±15.2	68.8±21.2*

Data are presented as mean±SD, unless otherwise stated.  $V_{O_2,peak}$ : peak oxygen uptake; HR: heart rate;  $V_{CO_2,peak}$ : peak carbon dioxide production; RER: respiratory exchange ratio;  $V_{E,peak}$ : peak ventilation; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension. <sup>†</sup>: incremental cycle ergometer test; <sup>\*</sup>: data given in mL·kg<sup>-1</sup>·min<sup>-1</sup>. <sup>\*</sup>: p<0.05 versus  $\delta$ MWT data.

TABLE 4 Relationship of 6-min walking distance to physical activity in adults with chronic respiratory disease

First author [ref.]	Diagnosis	Subjects n	Physical activity measure	Pearson's r	Spearman's rho
PITTA [72]	COPD	50	Walking time in daily life	0.75	
GARCIA-RIO [73]	COPD	110	Vector magnitude units on accelerometry	0.72	
HERNANDES [74]	COPD	40	Walking time in daily life	0.42	
			Intensity of movement	0.64	
HILL [75]	COPD	26	Daily energy expenditure	0.40	
BORGES [76]	COPD	20	Walking time in hospital		0.57
		20	Walking time in daily life 1 month after hospital discharge		0.71
TROOSTERS [77]	CF	64	Time spent in vigorous physical activity	0.45	
MAINGUY [78]	PAH-SSc	10	Number of daily steps	0.85	
	PAH	15	Number of daily steps	0.76	
	PAH	15	Energy expenditure	0.52	
	PAH	15	Time spent in moderate physical activity	0.52	
PUGH [79]	PAH	20	Total activity counts		0.72
LANGER [80]	LTC, COPD and ILD	96	Number of daily steps	0.65	
			Minutes of activity $\geq 2$ METS	0.58	
WICKERSON [81]	LTC, ILD	24	Number of daily steps	0.59	
			Time spent in moderate to vigorous physical activity	0.56	
DALE [42]	ARPD	25	Number of daily steps	0.38	

COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; PAH: pulmonary arterial hypertension; SSc: systemic sclerosis; LTC: lung transplant candidates; ILD: interstitial lung disease; ARPD: asbestos-related pleural disease; METS: metabolic equivalents.

#### Relationship of 6MWD to patient performance ratings

Studies in COPD and ILD demonstrated that patient perceptions of differences in their walking capacity were reflected by significant differences in the 6MWD, both in comparison with other patients [83] and pre- versus post-rehabilitation [84, 85].

#### Technical factors affecting 6MWT performance

The search strategy revealed 43 papers that were screened in full text, with 20 papers meeting the inclusion criteria.

#### Hallway versus treadmill

In two studies, a 6MWT performed on an externally paced treadmill was 13–20% lower than that performed in the hallway [20, 86]. This may be the result of the poor walking efficiency during treadmill walking in subjects unaccustomed to this activity [20].

#### Course location and layout

One study compared an indoor course with an outdoor course and reported little difference in 6MWD (mean difference 4 m) [87]. One large multicentre study showed a small benefit of circular versus linear track layout (mean difference 19 m; 5%) [6], and another also showed a slight increase in 6MWD on a circular track (mean difference 13 m; 3%) [88].

#### Track length

The effect of track length was examined in two studies. In one nonrandomised cross-sectional study in patients with severe COPD (candidates for lung volume reduction surgery), no differences in average outcome were found between tracks of 15–50 m [6]. In contrast, a randomised crossover study comparing track lengths of 30 m and 10 m in patients with moderate COPD found a mean increase in 6MWD of 49.5 m on the longer course (95% CI 39.4–59.6 m) [89]. The greater number of turns required for the very short track length probably contributes to this finding.

#### Walking aid

Six studies investigated the effect of a walking aid on 6MWD in people with COPD [90–95]. In all five studies investigating the effect of rollators, there was an improvement in 6MWD, ranging 2–46 m or 1–14%



(weighted mean 6.2% improvement). Two studies concluded that the benefits were seen most in those patients with more impaired walking distance. An additional study found that use of a modern draisine resulted in a longer 6MWD than the rollator (mean difference 83 m) [95].

#### Oxygen

All five studies comparing walking with and without oxygen showed an increased 6MWD when walking with oxygen supplementation in patients with COPD (mean difference 12–59 m) [96–100]. This increase in 6MWD may be further amplified when walking with oxygen is compared with walking with compressed air, due to the handicap of carrying the weight of the compressed air (mean difference 17–109 m) [99, 101].

#### Method of carrying the oxygen

One study showed that people with COPD who used a wheeled cart to carry their oxygen cylinder walked on average 23 m further than those who carried it on their shoulder [102]. A separate study demonstrated that if the patient carried the oxygen cylinder themselves, the beneficial effect of oxygen was smaller than if the oxygen was carried by an investigator (24 m *versus* 35 m improvement) [100].

#### Instructions

A study in 24 patients with ILD and PAH found an average increase in 6MWD of 52.7 m when the patient was asked to walk as “fast” as they could for 6 min, rather than the standard instruction of as “far” as they could in 6 min [103]. It was not clear whether the patients were naïve to the test or whether they were blinded to the purpose of the study.

#### Encouragement

No papers since 2000 have reported on the effects of encouragement. However, the effect of encouragement is generally recognised and was studied by GUYATT *et al.* [3] in 1984. These authors reported an average effect of encouragement every 30 s of 30.5 m.

#### Medication

Improvement in 6MWD following bronchodilator administration has been demonstrated in patients with COPD [104–107], although its magnitude appears small and may be clinically insignificant (mean difference 6–7 m) [106, 108].

#### *Relationship of 6MWD to clinical outcomes*

We identified 35 studies that assessed the association of 6MWD with mortality and/or hospitalisation in patients with chronic lung disease. 14 studies included patients with COPD [109–122], eight studies included patients with ILD [69, 123–129], nine studies included patients with PAH [43, 130–137] and four included studies patients with other chronic respiratory disease or on the list for transplantation [138–141]. Average 6MWD at baseline was between 300 and 450 m (fig. 1). Studies differed by population, source of recruitment, number of covariates in the statistical models and modelling of 6MWD in the analyses (*i.e.* as continuous or categorical variable). Therefore, we did not perform meta-analysis. Instead, we determined the proportion of studies that found a statistically significant association, defined by a p-value of  $\leq 0.05$ . We have referred to p-values from multivariate statistical models whenever possible.

In 13 (93%) out of the 14 COPD studies, a lower 6MWD was significantly associated with increased mortality (table S23) [109–122]. Two studies also assessed the association of 6MWD with hospitalisation and both of them (100%) found statistically significant associations [109, 120]. In patients with ILD, four (50%) out of eight studies found statistically significant associations of 6MWD with mortality (table S24) [69, 123–129]. Six (66%) out of nine studies in patients with pulmonary hypertension found statistically significant associations of 6MWD with mortality (table S25) [43, 130–137]. One assessed the association with hospitalisation and found a statistically significant association [134]. Finally, all four studies (100%) that included patients with other respiratory disease or on the list for transplantation found statistically significant associations of 6MWD with mortality (table S26) [138–141].

In summary, evidence from 27 (77%) out of 35 studies shows that lower 6MWD is consistently associated with increased mortality. There is less evidence for the association with hospitalisation, although it was consistently present in all the studies where it was assessed (n=3).

#### *Measurements and reporting for 6MWT*

The primary outcome measure for the 6MWT is distance (6MWD), reported in metres or feet. Other measures include exertional dyspnoea and fatigue, oxyhaemoglobin saturation, HR, 6MWD  $\times$  body weight (6-min walk work), and measures derived from a combination of these variables.




FIGURE 1 Thresholds of 6-min walking distance (6MWD) for the prediction of mortality in a) chronic obstructive pulmonary disease (COPD), b) interstitial lung disease (ILD), c) pulmonary arterial hypertension (PAH), and d) other chronic lung diseases. Vertical lines represent weighted mean thresholds for 6MWD across studies for predicting increased mortality.

### Dyspnoea

11 studies were included in this section: eight in COPD and three in ILD. Several authors have reported a relationship between 6MWD and modified Borg dyspnoea score in people with COPD [142–145], with correlation coefficients ranging from 0.39 to 0.49. Two studies showed that modified Borg score was an independent predictor of 6MWD [143, 145]. In 50 people with COPD and mean FEV<sub>1</sub> 45% predicted, the reduction in inspiratory capacity following a 6MWT was associated with the change in modified Borg score during the test ( $r^2=0.21$ ,  $p<0.0006$ ) [146]. Other studies have reported close relationships between modified Borg scores during the 6MWT in COPD and the severity of dyspnoea during daily life ( $r=0.54$ ) [147] and HRQoL ( $r=-0.69$ – $-0.43$ ) [58, 148].

In people with IPF, SpO<sub>2</sub> at the end of 6MWT was an independent predictor of modified Borg dyspnoea score ( $r^2=0.27$ ,  $p<0.0005$ ) [149]. In contrast, in sarcoidosis, the strongest predictor of modified Borg dyspnoea score during 6MWT was nonvolitional measures of respiratory muscle strength [150]. Modified Borg dyspnoea score after the 6MWT was also an independent predictor of HRQoL in people with sarcoidosis [151].

### Exertion or subjective fatigue

Subjective fatigue is an important symptom in people with a range of chronic lung diseases. 23 studies related to subjective fatigue were retrieved in full text and 12 were included in this section, all related to COPD [148–159].

All dimensions of subjective fatigue are higher in COPD compared with healthy aged subjects; almost half of the patients (47.2%) report fatigue every day compared with 13.5% of healthy individuals [159]. This is reflected during the 6MWT, where COPD patients experienced more subjective fatigue compared with healthy elderly subjects [55]. Patients with higher tumour necrosis factor- $\alpha$  reported more fatigue after 6MWD ( $p=0.054$ ) [153]. Dimensions of subjective fatigue have been related to pulmonary function, skeletal muscle force and quality of life in COPD patients [154, 155]. Subjective fatigue measured during the 6MWT using the Borg exertion scale is associated with lower 6MWT, slower gait speed, more severe lung disease, more dyspnoea on exertion and lower HRQoL (table S27) [148, 156–158]. Although there are fewer

data available to assess the impact of subjective fatigue during 6MWT compared with dyspnoea, existing studies support its role as an important contributor to 6MWD and disease status in COPD.

#### Heart rate responses

Nine studies were retrieved in full text. Three studies were excluded after full text review because of lack of pertinent data on HR responses. Six studies were included: three studies in PAH, two studies in IPF and one study in COPD.

HR responses may contribute to performance on the 6MWT in people with chronic respiratory disease. In a study using factor analysis, “HR pattern” was one of four factors that together explained 78.4% of the variance in 6MWD in 83 patients with severe COPD [145]. The components of “HR pattern” were HR at baseline and 6 min, maximum HR, increase in HR, HR at 2 min into recovery, and the HR recovery (HRR) at 2 min. Impairment in the HR response during the 6MWT, also known as “chronotropic response”, has been shown to predict 6MWD in idiopathic PAH (n=46) and nonidiopathic PAH (n=37) [160].

HRR refers to the reduction in HR with rest after the exercise period. In IPF, an abnormal HRR at 1 min (HRR<sub>1</sub>), defined as  $\leq 13$  beats, was a strong predictor of mortality [128]. Abnormal HRR<sub>1</sub> was also the strongest predictor of pulmonary hypertension in IPF on right heart catheterisation in multivariable analysis that included 6MWD (odds ratio 4.0, 95% CI 1.17–13.69; p=0.02) [161]. In PAH, HRR following 6MWT was consistently slowed in PAH patients compared with controls, and the best cut-off of HRR<sub>1</sub> to separate PAH patients from controls was 18 beats [162]. In 75 patients with IPAH, a HRR<sub>1</sub> <16 beats was found to be a strong predictor of clinical worsening [134].

In summary, the measurement of HR appears valuable and should be included in 6MWT assessments. Consideration should be given to measurement of HRR<sub>1</sub>; however, there is no universally accepted cut-off for this measure.

#### Oxyhaemoglobin saturation

Oxygen desaturation is commonly observed during the 6MWT in patients with lung diseases [163]. In a group of individuals with COPD and moderate to severe lung disease (mean FEV<sub>1</sub> 43% predicted), the prevalence of exercise-induced desaturation on 6MWT was 62%, where desaturation was defined as a drop of >4% in SpO<sub>2</sub> to <90% [164]. Desaturation during a 6MWT provides information regarding disease severity and prognosis in COPD [114, 115], ILD [123, 165], PAH [130] and SSc patients with pulmonary manifestations [82]. Desaturation during the 6MWT has been associated with more severe lung disease, higher levels of dyspnoea, poorer muscle strength, impaired daily physical activity and desaturation during daily life activities across a range of chronic respiratory diseases (table S28). These relationships support the clinical importance of quantifying desaturation during the 6MWT.

The 6MWT has been found to be more sensitive in identifying exercise-induced desaturation compared with cycle testing. In a study by POULAIN *et al.* [16], 28% of patients with COPD exhibited desaturation on 6MWT that was not observed on CPET. Other authors have reported similar findings [35, 37, 38]. The phenomenon was reproducible and not protocol dependent, emphasising the clinical interest of the 6MWT [16].

The 6MWT may be safe without continuous monitoring of SpO<sub>2</sub> [166]. However, continuous monitoring may be necessary to accurately record the extent of desaturation in patients with ILD and COPD. FIORE *et al.* [167] found that, although the end-6MWT SpO<sub>2</sub> and the nadir SpO<sub>2</sub> were similar in most patients with COPD and ILD, the end SpO<sub>2</sub> did not provide an accurate estimate of nadir SpO<sub>2</sub> in patients who rested during the test. A recent study in COPD reported similar findings, with 46% of patients exhibiting a “desaturation–resaturation” pattern, with nadir SpO<sub>2</sub> occurring relatively early in the test [168]. Therefore, constant monitoring of SpO<sub>2</sub> during the 6MWT is needed to obtain an accurate measure of exercise-induced desaturation.

#### Novel desaturation indices

A number of indices derived from desaturation measurements have been proposed in patients with ILD, with the aim of improving the predictive value of information gained from the 6MWT.

The distance–saturation product (DSP) (given in m%) is defined as the product of the final distance walked in metres and the lowest SpO<sub>2</sub> when breathing air. In 80 patients with IPF, a DSP  $\leq 200$  m% was associated with a markedly increased hazard ratio for mortality (6.5 (95% CI 3.1–12.7)) [125]. A subsequent study has shown that the DSP was not useful for detecting pulmonary hypertension in people with IPF who were listed for lung transplantation (DSP in those with pulmonary hypertension 272 m%, versus 286 m% in those without) [169].

A retrospective study in 59 individuals with sarcoidosis found that the DSP had a stronger relationship with measures of lung function, oxygenation and dyspnoea (standardised beta 0.45–0.59) than the 6MWD (standardised beta 0.19–0.52) [170]. The relationship between DSP and prognosis was not evaluated. The DSP also predicts HRQoL in sarcoidosis [151]. A model containing the DSP and end-6MWT modified Borg dyspnoea score was better able to predict SF-36 (short-form health survey) scores ( $R^2=0.33$ ) than a similar model where 6MWD was substituted for DSP ( $R^2=0.26$ ).

The desaturation area is defined as the total area above the curve between the  $SpO_2$  observed at each minute of the 6MWT and 100%. A higher desaturation area indicates higher overall desaturation during the 6MWT. FLAHERTY *et al.* [165] showed that, in a group of patients with IPF, for every 10-point increase in desaturation area there was an increased hazard ratio for mortality (1.30 (95% CI 0.97–1.75)). This measure has not been widely used.

The desaturation–distance ratio is a combination of 6MWD and desaturation area. One study in 49 people with ILD has shown a strong relationship between desaturation–distance ratio and measures of disease severity [171]. The prognostic value of this relatively complex measure has not been studied.

In summary, a number of newer measures incorporating desaturation are available for use in ILD. They are not routinely collected during the 6MWT and their utility has not been confirmed.

#### 6-min walk work

Body weight directly affects the work/energy required to perform the 6MWT. The 6-min walk work is the product of 6MWD and body weight, which may provide a better estimate of the work required to perform the test than distance alone. Three studies have investigated the use of 6-min walk work as an outcome of the 6MWT in COPD. The 6-min walk work correlates more strongly with  $V'O_{2peak}$  than 6MWD alone, with correlation coefficients of 0.67–0.81 *versus* 0.40–0.54, respectively [31, 33]. A similar pattern is seen with DLCO (0.60–0.70 *versus* 0.35–0.46) [31, 33]. The relationship between FEV1 and 6-min walk work has been reported as weak to moderate ( $r=0.2$ – $0.52$ ) [31, 33, 172]. None of the studies investigated the sensitivity of 6-min walk work to change over time. Additional studies are needed to better characterise the utility of 6-min walk work in adults with chronic respiratory disease.

#### Adverse events during the 6MWT

Reported complications associated with the performance of the 6MWT are unusual. Of the research that has been published to date, only two papers have specifically addressed the issue of complications associated with the test itself. Patients taking part in outpatient pulmonary rehabilitation ( $n=741$ ) completed the 6MWT with continuous monitoring of oxygen saturation and HR [163]. Adverse events were noted in 43 (6%) of tests. One test was terminated by a patient developing chest pain and another by a patient developing persistent tachycardia. In six tests, the patient developed symptoms and the test was discontinued. In 35 tests, the patient was instructed to discontinue walking because the  $SpO_2$  fell below 80%. In contrast, in a much smaller study in patients with ILD ( $n=19$ ) and DLCO 41% predicted, the 6MWT was allowed to continue if  $SpO_2$  fell below 80% [166]. No clinically significant cardiac arrhythmias were noted, despite marked desaturation in several participants.

Many patients who undergo a 6MWT develop oxygen desaturation [164]; however, significant adverse events appear to be very rare. Nevertheless, many previous studies have terminated the test before significant desaturation occurs [113, 123, 124, 163]. As a result, the safety of the 6MWT during severe desaturation ( $SpO_2 < 80\%$ ) has not been clearly documented.

#### Reference equations for the 6MWT

30 papers were reviewed in full text and 17 were included in this section, with reference equations shown in table 5. These studies were performed using a wide variety of populations and methodologies (table S29). This gives rise to substantial variation in the predicted 6MWD. Within groups of healthy people, independent predictors of the 6MWD include height, age, sex and weight (table 5). However, large differences in the predicted 6MWD occur among the published studies.

#### Site-to-site variation

In the Asociación Latinoamericana de Tórax (ALAT) study [173], Brazilian adults walked >100 m farther than subjects from Venezuela (638 *versus* 510 m). Some authors have concluded that different countries require specific equations for the 6MWD [173]. However, even between cities within a single country, large differences in mean 6MWD have been seen (*e.g.* 510 m from Zaragoza, Spain *versus* 613 m from Tenerife, Spain) [173]. A portion of the site-to-site differences were due to lower mean 6MWD from sites with a

TABLE 5 Reference equations for predicting the 6-min walking distance (6MWD) in healthy individuals

First author [ref.]	Sex	Reference equation	r <sup>2</sup>
CASANOVA [173]	Males	6MWD=361-(age × 4)+(height × 2)+(3 × HR <sub>max</sub> /HR <sub>max</sub> % <sub>pred</sub> )-(weight × 1.5)	0.09–0.73 <sup>#</sup>
	Females	6MWD=361-(age × 4)+(height × 2)+(3 × HR <sub>max</sub> /HR <sub>max</sub> % <sub>pred</sub> )-(weight × 1.5)-30	0.09–0.73 <sup>#</sup>
DOURADO [174]	Both	6MWD=299.296-(2.728 × age)-(2.160 × weight)+(361.731 × height <sup>m</sup> )+(56.386 × sex <sup>s</sup> )	0.54
	Both	6MWD=109.764-(1.794 × age)-(2.383 × weight)+(423.110 × height <sup>m</sup> )+(2.422 × grip strength)	0.54
HILL [175]	Both	6MWD=970.7+(-5.5 × age)+(56.3 × sex <sup>s</sup> )	
SOARES [176]	Both	6MWD=511+(height <sup>2</sup> × 0.0066)-(age <sup>2</sup> × 0.030)-(BMI <sup>2</sup> × 0.068)	
OSSES [177]	Males	6MWD=530-(3.31 × age)+(2.36 × height)-(1.49 × weight)	0.55
	Females	6MWD=457-(3.46 × age)+(2.61 × height)-(1.57 × weight)	0.63
ALAMERI [178]	Both	6MWD=(2.81 × height)+(0.79 × age)-28.5	0.25
BEN SAAD [179]	Both	6MWD=720.50-(1.60 × sex <sup>f</sup> )-(5.14 × age)-(2.23 × weight)+(2.72 × height)	0.77
IWAMA [180]	Both	6MWD=622.461-(1.846 × age)+(61.503 × sex <sup>s</sup> )	0.30
JENKINS [181]	Males	6MWD=867-(5.71 × age)+(1.03 × height)	
	Females	6MWD=525-(2.86 × age)+(2.71 × height)-(6.22 × BMI)	
MASMOUDI [182]	Both	6MWD=299.8-(4.43 × age)+(342.6 × height <sup>m</sup> )-(1.46 × weight)+(62.5 × sex <sup>f</sup> )	0.60
CAMARRI [183]	Both	6MWD=64.69+(3.12 × height)+(23.29 × FEV <sub>1</sub> )	0.43
	Both	6MWD=216.90+(4.12 × height)-(1.75 × age)-(1.15 × weight)-(34.04 × sex <sup>f</sup> )	0.36
CHETTA [184]	Both	6MWD=518.853+(1.25 × height)-(2.816 × age)-(39.07 × sex <sup>f</sup> )	0.42
POH [185]	Both	6MWD=(5.50 × HR <sub>max</sub> /HR <sub>max</sub> % <sub>pred</sub> )+(6.94 × height)-(4.49 × age)-(3.51 × weight)-473.27	0.78
GIBBONS [186]	Both	6MWD=868.8-(age × 2.99)-(sex <sup>f</sup> × 74.7)	0.41
ENRIGHT [187]	Males	6MWD=510+(2.2 × height)-(0.93 × weight)-(5.3 × age)	0.20
	Females	6MWD=493+(2.2 × height)-(0.93 × weight)-(5.3 × age)	0.20
TROOSTERS [188]	Both	6MWD=218+(5.14 × height)-(5.32 × age)-(1.80 × weight)+(51.31 × sex <sup>s</sup> )	0.66
ENRIGHT [189]	Males	6MWD=(7.57 × height)-(5.02 × age)-(1.76 × weight)-309	0.42
	Females	6MWD=(2.11 × height)-(2.29 × weight)-(5.78 × age)+667	0.38
	Males	6MWD=1.140-(5.61 × BMI)-(6.94 × age)	
	Females	6MWD=1.017-(6.24 × BMI)-(5.83 × age)	

Units are as follows, unless otherwise stated. 6MWD: m; age: years; height: cm; weight: kg; grip strength: kg; body mass index (BMI): kg·m<sup>-2</sup>; forced expiratory volume in 1 s (FEV<sub>1</sub>): L. HR<sub>max</sub>/HR<sub>max</sub>%<sub>pred</sub>: maximum heart rate during the 6-min walk test divided by the predicted maximum heart rate. #: adjusted r<sup>2</sup> values for males and females; <sup>m</sup>: in m; <sup>s</sup>: males=1, females=0; <sup>f</sup>: males=0, females=1.

lower mean exercise intensity (end-of-exercise HR as a percentage of estimated maximum HR(%max HR)), probably due to variations in test administration.

#### Effect of race/ethnicity

Many authors have concluded that differences in mean 6MWD between their study and previous studies of Caucasians were due to racial or ethnic differences [174, 178, 182, 185, 190]. However, because of differences in protocols, and thus in the exercise intensity, it is difficult to interpret differences between studies performed at a single site with a single race/ethnic group. Only one study included two different racial groups at the same sites, allowing a direct comparison [187]. Using a regression model, this study of healthy elderly people reported a mean 6MWD for African-Americans 39 m lower than for Caucasian subjects. Similar within-study comparisons have not been reported for other age groups or other racial/ethnic groups.

#### Methodological differences

The mean walking distances obtained from the healthy participants in the Cardiovascular Health Study [187] were relatively low because participant instructions were to “walk from end to end of the hallway at your own pace.” Many studies published after the ATS guidelines [2] have reached higher values of 6MWD. In these studies, assessors asked the subjects to reach the farthest possible distance in 6 min, which may prompt a higher walking speed.

#### Exercise intensity

Mean exercise intensity (%max HR) varied from 44% to 81% between studies that reported this outcome [191]. Exercise intensity may be influenced by the technician and by the patient’s motivation. Higher exercise intensity provides a higher 6MWD (after adjusting for other factors using linear regression models). Some investigators have produced 6MWD prediction equations which include measured %max HR [185].

However, caution is needed when using this approach for patients aged  $\geq 40$  years, since patients with clinically apparent cardiopulmonary disease often have a higher HR at a given level of exercise (when compared with healthy people), which would cause their %max HR to be elevated, causing an overestimation of their exercise intensity. Conversely, those taking beta-blockers for hypertension or coronary artery disease have attenuation of %max HR [176], causing an underestimation of their exercise intensity.

#### Number of tests

The authors of some 6MWD reference equations performed only one test, while investigators of other studies always performed two tests and reported the highest 6MWD obtained (table S29). The mean improvement in 6MWD when performing two 6MWTs is approximately 26 m [8], so this does not fully explain the much larger mean differences between studies.

#### Identifying meaningful change in the 6MWD

##### Minimal important difference of the 6MWD

We evaluated the full text of 22 studies (table S30) and finally included studies that assessed the MID in patients with COPD (six studies), ILD (three studies) and PAH (two studies). Table S31 shows the study and participant characteristics. The >5600 patients included in these studies had moderate to severe lung disease and received rehabilitation, drug treatments, lung volume reduction surgery or no treatment. Mean baseline 6MWD ranged from 343 to 403 m.

Table 6 summarises the methods and outcomes of studies used to determine the MID. The majority of estimates are based on distribution-based methods because correlations with potential anchors were too low for anchor-based methods. Three studies in COPD, all three in ILD and one study in PAH also provided anchor-based estimates. Figure 2 shows all estimates for the MID. There is relatively little variability across patient groups. Estimates based on anchor-based methods ranged from 21.6 to 38.6 m, with a median estimate across studies of 24.8 m. Distribution-based estimates varied more (range 26–57 m), with a median estimate of 32.1 m, which can be explained by different effect-size-based methods used in different studies. The study by REDELMEIER *et al.* [83] used an entirely different approach, where patients estimated the difference between themselves and other patients during rehabilitation. The estimate from that study was 54 m. Across all estimates (based on any method), the median estimate was 30 m.

The available evidence suggests a MID of 30 m for adult patients with chronic respiratory disease. There is some variability across studies and methods to determine the MID; however, based on the large evidence base now available, we can be confident that the MID lies between 25 and 33 m.

#### Responsiveness of the 6MWD

Responsiveness is the capacity of a measure to detect meaningful change over time. Relatively few studies have been explicitly designed to assess the responsiveness of 6MWD but a large number of randomised trials provide insights into how responsive 6MWD is to treatment effects. Therefore, we selected systematic reviews from the Cochrane Collaboration that evaluated interventions where change in 6MWD is expected to occur. We chose the Cochrane reviews on exercise interventions for COPD and ILD and the Cochrane review on endothelin receptor antagonists for PAH, to illustrate the responsiveness of 6MWD.

For COPD, the reviews by LACASSE *et al.* [199] and PUHAN *et al.* [200] summarised the trials on pulmonary rehabilitation *versus* usual care in patients with stable COPD and after a COPD exacerbation, respectively. In the review of trials in stable COPD patients, 16 trials reported on 6MWD, of which 15 reported improvements of 6MWD with rehabilitation compared with usual care. Most trials were underpowered to detect statistically significant effects, but the meta-analysis showed an average improvement of 48 m (95% CI 32–65 m;  $p < 0.0001$ ) [199]. The effect size (pooled estimate divided by pooled standard deviation of change in the control group) as a measure for responsiveness was 0.51. In the review in patients after a COPD exacerbation, six trials reported on 6MWD, of which four reported statistically significant improvements of 6MWD with rehabilitation compared with usual care and two trials reported no improvements. The meta-analysis showed an improvement of 78 m (95% CI 12–143 m;  $p < 0.0001$ ) with a corresponding effect size of 1.07 (median standard deviation of change in control group of 73 m) [200].

The systematic review on physical exercise training in patients with ILD identified two trials that reported on 6MWD [201]. Both trials comparing exercise with usual care showed statistically significant improvement of 6MWD and the meta-analysis showed an improvement of 39 m (95% CI 15–62 m). The corresponding effect size was 0.65 (median standard deviation of change in control group of 58 m).

11 trials reported on the effects of selective and nonselective endothelin receptor antagonists *versus* placebo on 6MWD in patients with PAH [202]. 10 trials showed an improvement of 6MWD but in only six trials was the effect statistically significant. The meta-analysis showed a statistically significant improvement of

TABLE 6 Minimal important difference (MID) estimates for 6-min walking distance in patients with chronic respiratory disease

First author [ref.]	Patient population	Study design	Intervention	MID estimation		Proposed MID
				Anchor-based	Distribution-based	
<b>REDELMEIER [83]</b>	Moderate to severe COPD	Prospective, single arm	Rehabilitation	NA	NA	54 m
<b>WISE [192]</b>	Severe to very severe COPD	Prospective, single arm within RCT	None (test-retest)	NA	SEM: 45.3 m; ES: 47.0 m; CRM: 80.0 m; average across three estimates: 57.4 m SEM: 35 (30–42) m; ERES: 42 m; average across three estimates: 35.3 m SRM: 1.2; SEM: 25.5 m; average across two estimates: 26.0 m ES: 26.8 m; SEM: 30.6 m; ERES: 25.7 m; average across three estimates: 27.7 m	Between-patient ratings: 54 m NA No specific estimates (range 45–80 m)
<b>PUHAN [193]</b>	Moderate to severe COPD	Prospective, single arm	Rehabilitation	NA	NA	35 m (triangulation)
<b>HOLLAND [84]</b>	Moderate to severe COPD	Prospective, single arm	Rehabilitation	25 (20–61) m	NA	25 m (triangulation)
<b>PUHAN [194]</b>	Severe to very severe COPD	RCT	LVRS or medical treatment	18.9 (18.1–20.1) m; 24.2 (23.4–25.4) m; 24.6 (23.4–25.7) m; 26.4 (25.4–27.4) m; average across four estimates: 23.5 m	NA	26 m (triangulation)
<b>POLKEY [195]</b>	Mild to very severe	Prospective, observational	None	30 m	NA	30 m
<b>HOLLAND [85]</b>	Moderate to severe DPLD (50% IPF)	Prospective, single arm	Rehabilitation	30.5 m	SEM: 33 m	30–33 m
<b>SWIERIS [196]</b>	Moderate to severe IPF	RCT	Bosentan	21.6 m	41.3 m	28 m (mean of all MIDs)
<b>DU BOIS [62]</b>	Moderate to severe IPF	RCT	Interferon- $\gamma$ -1b	24 m	SEM: 45 m	No specific estimates (range 24–45 m)
<b>GILBERT [197]</b>	Moderate to severe PAH	RCT	Sildenafil (three different dosages)	NA	ES: 31.2 m; SEM: 24.7 m; Sdiff: 37.8; average across three estimates: 31.2 m ES: 38.5 m; SRM: 0.2; SEM: 25.1 m; average across three estimates: 30.8 m	41 m (median across all estimates)
<b>MATHAI [198]</b>	Moderate to severe PAH	RCT	Tadalafil or placebo	38.6 m	NA	33 m (triangulation)

Data are presented as value [95% CI], unless otherwise stated. COPD: chronic obstructive pulmonary disease; NA: not available; RCT: randomised controlled trial; SEM: standard error of the measurement; ES: effect size (0.5  $\times$  baseline SD); CRM: coefficient of repeated measurements; ERES: empirical rule effect size; SRM: standardised response mean (mean change/SD of change); LVRS: lung volume reduction surgery; DPLD: diffuse parenchymal lung disease; IPF: idiopathic pulmonary fibrosis; PAH: pulmonary arterial hypertension; Sdiff: standard error of the difference, a measure of errors associated with longitudinal change in a measure,  $Sdiff = \sqrt{((SEM \text{ at baseline})^2 + (SEM \text{ at end of treatment})^2)}$ .




FIGURE 2 Minimal important difference (MID) estimates for 6-min walking distance (6MWD) in chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). The numbers next to the estimates describe the MID proposed by a study (e.g. by taking the median of all estimates or by triangulation).

34 m (95% CI 25–43 m) with a corresponding effect size of 0.38 (median standard deviation of change in control group of 89 m).

In summary, 6MWD appears to be responsive to treatment effects in patients with COPD, ILD and PAH, although the majority of the data relate to rehabilitation and few trials were available to evaluate responsiveness to pharmacological treatments. The standardised response means (mean change/standard deviation of change) ranged from 0.2 to 1.2 (table 6). Single trials were often underpowered to show statistically significant results, which may be attributable to a relatively large variability in 6MWD in patients with chronic respiratory disease. Trials either need to include a large number of patients (several hundred) or show a large effect (>100 m) to detect a statistically significant signal. The meta-analyses confirmed this as they showed highly statistically significant results with effects between 34 and 78 m and effect sizes between 0.38 and 1.07.

### ISWT

The ISWT was first described in 1992 to assess exercise capacity in patients with COPD [203]. Compared with the 6MWT there is a smaller but emerging literature on the conduct and properties of the test in chronic respiratory disease. The ISWT offers a different protocol to the 6MWT as it is both incremental and externally paced, conducted around a 10-m course.

The search returned a total of 224 records, after removal of duplicates. After removal of records that were not related to the ISWT or individuals with respiratory disease, 168 records remained. Three additional references were identified in the updated search in September 2013.

#### Reliability of the ISWT

There are a number of studies (n=7) describing the reliability of the ISWT (table 7). The majority of the data are from patients with COPD. One study reported an ICC of 0.88 with a 95% CI of 0.83–0.92 [205]. Following subgroup analysis on sex, age and severity, the ICC remained high (range 0.80–0.93). A second study reported inter-subject variability as 88.9% [7]. These two studies suggest that the association between test–retest ISWT distances is strong, with the majority of variability being attributable to between-subject differences rather than within-subject differences.

#### Learning effect on ISWT

There is a significant learning effect between the first two ISWTs, with mean differences ranging 9–25 m (pooled mean difference 20 m; n=640 subjects) (table 7). This is of sufficient magnitude to recommend two tests at first exposure. The learning effect may be attenuated over subsequent repeats of the test [7].



TABLE 7 Reliability of incremental shuttle walk test (ISWT) distance in chronic respiratory disease

First author [ref.]	Diagnosis	Mean age years	Severity	Methods	ICC	Mean difference m	Coefficient of repeatability	Least square differences
<b>ARNARDÓTTIR [204]</b>	COPD	64	Moderate to severe	Repeat test 7 days later in subgroup, no practice tests, test 1 versus test 2		9 ± 38	74.5 <sup>#</sup>	
<b>CAMPO [205]</b>	COPD	68.6	Mild to severe	Test–retest, 1 week apart (practice walks performed), operators not blinded, 10 min between practice and a test	0.88 [0.83–0.92]			
<b>DYER [206]</b>	Chronic airflow limitation	76	Mild to moderate	Test 1 versus test 3, within 2 weeks, (no practice walk on day 1), operators not blinded		6 ± 17.89	35.1 m	
<b>DYER [207]</b>	Mixed chronic lung diseases	70	Mild to severe	Repeatability of test 1 versus test 2 (i.e. practice versus actual) on separate days		23.5 ± 47.3	92.7 <sup>#</sup>	
<b>EISER [7]</b>	COPD	69	Moderate to severe	Nine ISWTs performed over 3 weeks (3 tests-day <sup>-1</sup> ), difference within and between days	0.89			Inter-subject 10 m, intra-subject 11 m, inter-subject variability 88.9%, intra-subject variability 9.2%
<b>HILL [48]</b>	COPD	66.5	Mild to severe	Practice and actual performed on same day, difference calculated as learning effect		25 ± 35	68.6 <sup>#</sup>	
<b>MCKEOUGH [208]</b>	COPD	72	Moderate to severe	Test 1 versus test 2 (pre-exercise training), test 3 versus test 4 (post-exercise training), no practice walks		Test 1 versus 2: 20 [9–31], test 3 versus 4: 19 [6–30]		
<b>ZAINULDIN [209]</b>	COPD	70	Mild to severe	Two tests on the same day, 30 min rest between		18 [14–22]		

Data are presented as mean ± SD or value [95% CI], unless otherwise stated. ICC: intra-class correlation coefficient; COPD: chronic obstructive pulmonary disease. <sup>#</sup>: coefficient of repeatability calculated from published data as SD of differences × 1.96.

However, there is a suggestion that over longer periods (>8 weeks) the learning effect may reset to a level similar to that recorded at first test exposure [208]. This observation requires further corroboration. There are no data available that indicate whether the repeatability of the test varies with baseline performance; therefore, it is important that two tests are performed regardless of functional capacity.

#### Reliability of other measures taken during the ISWT

Two studies evaluated reliability of end-test SpO<sub>2</sub> and HR measures for ISWTs repeated within the same day [48, 208]. These variables appear to repeat well with only small differences reported (mean difference: HR 0–4% and SpO<sub>2</sub> 0%). Two studies report measurements of symptom scores recorded during repeat ISWTs [7, 208]. The modified Borg dyspnoea score may be more reproducible than the visual analogue score [7]. The mean  $\pm$  SD difference between Borg fatigue scores was  $0 \pm 2$  units [208].

#### Validity of the ISWT

The aim of developing the ISWT was to derive a field-based exercise test that could reflect the response provoked by a CPET. Validation of the ISWT, therefore, has focused largely on direct comparison with incremental exercise tests conducted in the laboratory. Studies that met the inclusion criteria are shown in table 8. The data show a strong relationship between V<sub>O<sub>2</sub></sub> or work rate on CPET and ISWT ( $r=0.75$ – $0.88$ ) [35, 38, 204, 210], with no difference in measured V<sub>O<sub>2</sub></sub> between the tests [48, 209, 211]. Other physiological parameters (V<sub>CO<sub>2</sub></sub>, V<sub>E</sub> and derivatives) were generally lower during the ISWT (table 8). Minute-by-minute analysis of both the ISWT and CPET demonstrated a linear response in V<sub>O<sub>2</sub>peak</sub>, suggesting that the two tests provoke a similar cardiopulmonary response [48]. The current literature suggests that the ISWT is a valid measure of cardiopulmonary exercise capacity in COPD. It should also be noted that most of the data are obtained from individuals with COPD with moderate to severe disease and usually confined to small study populations.

The ISWT has been shown to be related to other outcomes in people with chronic respiratory disease. In COPD, demographics such as age, sex and lung function are weakly related to ISWT distance ( $r=0.29$ – $0.38$ ) [206, 213, 214]. The distance walked in the ISWT correlates moderately with the sniff nasal inspiratory pressure in patients with lung cancer ( $r=0.42$ ) [215]. The ISWT distance also has a moderate correlation with quadriceps muscle strength in COPD ( $r=0.47$ ) [214] and lung cancer ( $r=0.39$ ) [215]. Two studies described a weak to moderate relationship of ISWT distance with objectively measured levels of physical activity in daily life ( $r=0.17$ – $0.58$ ) [216, 217].

#### Technical factors affecting ISWT performance

There were no data available on track layout. This would be expected, as the course to conduct the ISWT is clearly defined and not subject to variation. No data were available for differences that might be associated with different operators or the impact of encouragement. One paper examined seasonal variation and found no important differences in performance, although these tests were conducted indoors [218]. Compared with walking with a compressed air cylinder, oxygen supplementation during ISWT increased distance by 33 m (95% CI 18–47 m) in patients who were hypoxic at rest or had exercise-induced desaturation [219]. However, there was no difference when the oxygen-supplemented walk was compared with the baseline walk without a cylinder (mean difference 4 m, 95% CI -11–18 m) [219], highlighting the importance of whether the cylinder is supported by the individual or the clinician/researcher.

#### Relationship of ISWT to clinical outcomes

The ISWT may be a useful marker of clinical outcomes, although the data are reported from a small number of studies (table 9). The ISWT appears to be a significant predictor of survival and re-admission in people with COPD, those with a lower performance having a greater risk of admission [220, 222, 223]. A threshold of <170 m has been suggested to be associated with higher mortality [222]; however, these data have not yet been replicated.

#### Measurements and reporting for ISWT

Complications associated with the performance of the ISWT are unusual. We were unable to find specific published reports of complications or adverse events associated with performance of the ISWT in clinical trials. The safety of the test has only been described in cardiac disease [224], with no adverse events reported. One study that included 50 participants with mild-to-severe COPD and who had experienced no exacerbation in the previous 6 weeks reported that the mean  $\pm$  SD change in saturation was  $-4.6 \pm 6.2\%$  after the ISWT [225].

Performance on the ISWT is defined by the distance achieved. This is expressed in 10-m increments. The level and number of shuttles achieved can also be reported as outcomes for ISWT. Other outcomes reported

TABLE 8 Relationship of incremental shuttle walk test (ISWT) to other exercise tests in people with chronic respiratory disease

First author [ref.]	Diagnosis	Mean age years	Disease severity	Subjects n	Comparison test	Results
ARNARDÓTTIR [204]	COPD	64	Moderate to severe	93 <sup>#</sup>	CPET	$r=0.88$ , $p<0.0001$ ISWT distance $\times$ body weight versus $W_{peak}$
CAMPO [205]	COPD	68.6	Mild to severe	30	6MWT, 12MWT, CPET	$r=0.82$ ISWT versus 6MWT; $r=0.74$ ISWT versus 12MWT;
HILL [48]	COPD	67	Mild to severe	24	CPET	$r=0.68$ estimated $V'O_2$ versus $V'O_{2max}$ No difference in $V'O_2$ between ISWT and CPET (mean 1227 versus 1186 mL·min <sup>-1</sup> )
LUXTON [38]	COPD	65	Moderate to severe	25 (22 <sup>†</sup> )	CPET	$r=0.75$ ISWT distance versus CPET $W_{peak}$ ; $r=0.85$ ISWT distance $\times$ weight versus CPET $W_{peak}$ ; significant mean difference: $V'CO_2$ ( $p=0.001$ ), $V'E$ ( $p=0.006$ ), $SpO_2$ ( $p<0.001$ ), RPE ( $p<0.001$ ), Borg dyspnoea ( $p=0.001$ )
ONORATI [210]	COPD	70	Moderate	13	CPET	$r=0.92$ ISWT $V'O_{2peak}$ versus $V'O_{2peak}$ cycling; $r=0.86$ ISWT $V'O_{2peak}$ versus ISWT distance; $r=0.72$ ISWT distance versus $V'O_{2peak}$ cycling
PALANGE [211]	COPD	71	Moderate	9 (7 <sup>†</sup> )	CPET	Mean $V'O_{2peak}$ 1145 versus 1025 mL·min <sup>-1</sup> (NS) for CPET versus ISWT; significant mean difference: $V'CO_{2peak}$ ( $p<0.001$ ), RER ( $p<0.001$ ), HR/ $V'O_2$ ( $p<0.05$ ), $V'E/V'CO_{2peak}$ ( $p<0.001$ ), $V'E/V'CO_2$ ( $p<0.001$ ), lactate ( $p<0.001$ ), dyspnoea ( $p<0.05$ ), leg effort ( $p<0.05$ )
TURNER [35]	COPD	64	Moderate to severe	20	CPET	$r=0.73$ ISWT distance versus ISWT $V'O_{2peak}$ ; $r=0.79$ ISWT distance versus CPET $V'O_{2peak}$
WIN [212]	Lung cancer	69	Operable	125	Treadmill CPET	$r=0.67$ $V'O_{2peak}$ CPET versus ISWT distance
ZAINULDIN [209]	COPD	70	Mild to severe	34	CPET	No difference in $V'O_{2peak}$ CPET versus ISWT: mean (95% CI) difference 0.024 (-0.036–0.085) L·min <sup>-1</sup> ; on ISWT, significantly lower $V'CO_2$ , $V'E$ , $V'E/MVV$ , $SpO_2$ , symptoms

All ISWTs had a cohort study design. COPD: chronic obstructive pulmonary disease; CPET: cardiopulmonary exercise test;  $W_{peak}$ : peak work rate; 6MWT: 6-min walk test; 12MWT: 12-min walk test;  $V'O_2$ : oxygen uptake;  $V'O_{2max}$ : maximum oxygen uptake;  $V'CO_2$ : carbon dioxide production;  $V'E$ : minute ventilation;  $SpO_2$ : arterial oxygen saturation measured by pulse oximetry; RPE: rate of perceived exertion;  $V'O_{2peak}$ : peak oxygen uptake; NS: nonsignificant;  $V'CO_{2peak}$ : peak carbon dioxide production; RER: respiratory exchange ratio; HR: heart rate; MVV: maximum voluntary ventilation. #: convenience sample; †: completers.

include HR and blood pressure responses,  $SpO_2$ ,  $V'O_2$ ,  $V'E$ , respiratory rate, inspiratory capacity, dyspnoea and leg fatigue, monitored before and during the test. Despite systematic effort, we were unable to find published reports showing how different monitoring protocols affect detection of changes in performance or clinical outcomes during shuttle walking tests in patients with chronic respiratory diseases.

Four studies demonstrated the utility of  $SpO_2$  during the ISWT. Significant desaturation during the test has been reported [219], which may be greater than during the 6MWT [225]. Two studies recorded desaturation following the ISWT compared to a CPET [35, 226]. One study reported improvement in  $SpO_2$  and a reduction in breathlessness score when supplemental oxygen was administered during the ISWT [219].

In summary, the ISWT distance is the primary outcome and should be recorded on every test. Due to absence of supportive data, but being mindful of potential cardiovascular problems as well as exercise-induced hypoxaemia during walking exercise [35, 219], it seems reasonable to continuously monitor  $SpO_2$  and HR during the test, with recording of the lowest  $SpO_2$  and the peak HR.

#### Reference equations for ISWT

There have been three papers describing reference values for the ISWT. In total, 411 healthy adults have been recruited, with two studies conducted in South America contributing the most data [227, 228]. The largest study has a median age of 50 years, which is at least a decade younger than that observed in pulmonary rehabilitation. The reference equation from this group included age, sex and body mass index (BMI) as the important variables, explaining 71% [228] and 50% [227] of the variability. The third study,

TABLE 9 Relationship of incremental shuttle walk test (ISWT) to clinical outcomes

First author [ref.]	Diagnosis	Mean $\pm$ SD age years	Disease severity	Study design	Outcomes	Result
EMTNER [220]	COPD post exacerbation	65 $\pm$ 9.5	Severe	Prospective cohort	ISWT and hospitalisation	Mean $\pm$ SD ISWT: hospitalisation at 12 months (n=9) 174 $\pm$ 124 m, no hospitalisation at 12 months (n=12) 358 $\pm$ 94 m, p=0.001 between groups; hazard risk ratio of hospitalisation at 12 months was 0.80 (95% CI 0.67–0.97) per 10 m
KETCHELL [221]	CF	24	End-stage	Retrospective	ISWT and survival	No significant association between distance on the ISWT and survival
RINGBAEK [222]	COPD	68.0 $\pm$ 9.3	Severe	Cohort	ISWT and survival	Hazard ratio of mortality in patients who achieved <170 m versus patients who achieved $\geq$ 170 m was 2.83 (95% CI 2.05–3.90) in univariate analysis and 2.84 (95% CI 2.05–3.93) in multivariate analysis, p<0.05; the two highest quartiles of ISWT distance were equal in the regression model, suggesting the association is not linear
WILLIAMS [223]	COPD	68.9 $\pm$ 9.0	Moderate to severe	Observational, cohort	Incorporating the ISWT into the BODE score (FEV <sub>1</sub> % predicted, MRC and BMI), age, pack-years, GOLD stage, FVC and survival	BMI, MRC, ISWT, age and pack-years significantly associated with survival; hazard ratio for death per 1-point increase on i-BODE score was 1.27 (95% CI 1.18–1.36), p<0.001

COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; BODE: body mass index, airflow obstruction, dyspnoea and exercise capacity; FEV<sub>1</sub>: forced expiratory volume in 1 s; MRC: Medical Research Council dyspnoea score; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FVC: forced vital capacity; i-BODE: BODE index incorporating ISWT.

from a single centre in the UK [229], included measures of strength and physical activity. The addition of these measures to FEV<sub>1</sub> and BMI did not improve the reference equation, which explained only 50% of the variance. This study did not find a sex difference in performance of the ISWT once corrected for age.

#### Identifying meaningful change in the ISWT

##### Minimal important difference of the ISWT

Based on the titles and abstracts, only two studies, conducted in participants with confirmed COPD, were retained [230, 231]. The first report provided a MID estimate for the ISWT in 372 patients with moderate to very severe airflow limitation and a mean  $\pm$  SD baseline ISWT distance of 168.5  $\pm$  114.6 m undertaking 7 weeks of pulmonary rehabilitation [230]. The MID estimate was determined with an anchor-based method, where change in ISWT distance was related to the patients' perception of change from baseline, rated on a 5-point Likert scale. A mean change of 47.5 m (approximately five shuttles) was associated with the rating "slightly better", while a mean change of 78.7 m (approximately eight shuttles) was associated with the next rating ("better"). The authors concluded that the MID for the ISWT was 47.5 m. Similar results were reported in a study of 261 patients with COPD undertaking pulmonary rehabilitation [231]. A mean change of 45.7 m was associated with the rating "a little better".

#### Responsiveness of the ISWT

Three studies were explicitly designed to evaluate the responsiveness to treatment of the ISWT, following bronchodilation [206], ambulatory oxygen therapy [219] or pulmonary rehabilitation [232]. Characteristics of the included studies can be seen in table S32. Overall, the studies suggested that the ISWT was responsive to the interventions tested, with standardised response means (mean change/standard deviation of change) ranging from 0.72 to 1.55 (table 10).

Two systematic reviews aimed to study the effects of pulmonary rehabilitation after acute exacerbation on subsequent hospital admissions, mortality, HRQoL and exercise capacity compared with usual care in

TABLE 10 Studies designed to assess responsiveness of the incremental shuttle walk test (ISWT) and endurance shuttle walk test (ESWT) to interventions of known efficacy

First author [ref.]	Studied population				Field tests			SRM
	Population	Subjects n	Mean age years	FEV1	Field test studied	Mean field test distance or time at baseline	Mean change in walking distance or time	
<b>DYER [206]</b>	Elderly with CAL	50	76	72% pred	ISWT	177.7 m	13.2 ± 4.8% [-28.5-61.3%]	NA
<b>PEPIN [105]</b>	COPD	17	65	56% pred	ESWT	405 s	164 ± 177 s <sup>#</sup>	0.93
<b>PEPIN [106]</b>	COPD GOLD stage II-III	14	64	50% pred	ESWT	420 m	144 ± 219 m <sup>#</sup>	0.66
						253 s		
<b>BROUILLARD [107]</b>	COPD	20	65	52% pred	6MWT	553 m	7 ± 17 m	0.42
<b>SANDLAND [219]</b>	Severe hypoxaemic COPD	41	71	0.85 L	ESWT	373 s	117 ± 208 s <sup>#</sup>	0.56
					ISWT	192.4 m	33.2 ± 46.3 m <sup>#</sup>	0.72
<b>REVILL [233]</b>	COPD with exertional desaturation	23	67	33% pred	ESWT	156.0 m	112.0 ± 217.1 m <sup>#</sup>	0.52
					ESWT	273 s	91 [43-139] s <sup>#</sup>	NA
						221 m	66 [27-106] m <sup>#</sup>	
<b>EATON [234]</b>	COPD	20	71	0.95 L	6MWT	309 m	6 [-6-19] m	NA
					ESWT	313 m	302 ± 387 m <sup>#</sup>	0.78
<b>LEUNG [232]</b>	COPD GOLD stage I-IV, walking training group	17	71	56% pred	6MWT	351 m	47 ± 79 m <sup>#</sup>	0.59
	COPD GOLD stage I-IV, cycling training group	15	72	53% pred	ISWT	402 m	54 ± 37 m <sup>†</sup>	1.46
					ESWT	397 s	439 ± 346 s <sup>†</sup>	1.27
					ISWT	373 m	45 ± 29 m <sup>†</sup>	1.55
					ESWT	375 s	160 ± 204 s <sup>†</sup>	0.78

Data are presented as mean ± standard error of the measurement (95% CI), unless otherwise stated. FEV1: forced expiratory volume in 1 s; SRM: standardised response mean [mean change/SD of change]; CAL: chronic airflow limitation; NA: not available and/or incalculable; COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; 6MWT: 6-min walk test. <sup>#</sup>: p<0.05; <sup>†</sup>: p-value NA.

TABLE 11 Reliability of the endurance shuttle walk test (ESWT) in chronic obstructive pulmonary disease

First author [ref.]	Mean age years	Disease severity	Method of repeatability/reliability	Result	Comments
McKEOUGH [208]	72	Moderate	Test 1 versus test 2 (pre-exercise training), test 3 versus test 4 (post-exercise training)	Test 1 versus test 2 mean difference 2 s ( $p=0.95$ ), test 3 versus test 4 mean difference 44 s ( $p=0.07$ )	Repeatability pre- and post-8–12 weeks cycling or tai chi training, ESWT at 85% of best ISWT
REVILL [240]	68	Severe	Test 1 versus test 2	Test 1 versus test 2 mean difference 12 s (95%CI -3–28 s)	ESWT at 85% on best ISWT, same Borg dyspnoea score at the end of both tests in 77% of sample, Bland-Altman shows limits of agreement $\pm 100$ s
HILL [48]	67	Mild to severe	Test 1 versus test 2 on same day	Test 1 versus test 2 mean $\pm$ SD difference $50 \pm 83$ s, $n=18$	Mean differences between tests: heart rate 2 bpm, $SpO_2$ 1%

ISWT: incremental shuttle walk test;  $SpO_2$ : arterial oxygen saturation measured by pulse oximetry.

COPD [235, 236]. The meta-analysis, including 128 COPD patients, reported a weighted mean difference of 64.35 m (95% CI 41.28–87.43 m) in ISWT distance, favouring rehabilitation.

In summary, very few systematic reviews have reported changes in ISWT after interventions of known effectiveness, but studies designed specifically to assess responsiveness to treatment suggest that the ISWT is responsive.

### ESWT

The ESWT is a test of endurance capacity, first described in 1999 [237]. It is externally paced and is performed along the same course as the ISWT. The pace of the ESWT is traditionally calculated at a pre-defined percentage of peak performance on the ISWT (e.g. 70–85% estimated  $V'O_{2peak}$ ) [238]. However, recent data have indicated that the speed can also be accurately derived using 85% of walking speed on the ISWT [239].

The search returned a total of 60 records after removal of duplicates. After removal of studies unrelated to ESWT or respiratory disease, a total of 56 records remained.

#### Reliability of the ESWT

Three studies have examined the reliability of the ESWT, all in people with COPD (table 11) [48, 208, 240]. The differences between tests repeated on the same day were generally small and statistically nonsignificant (pooled mean difference +26 s). Two tests do not appear to be necessary, although it is acknowledged that the number of studies is limited. Measurements of HR,  $SpO_2$  and modified Borg dyspnoea scale appear to repeat well during the test [48, 240]. The reliability of the test in other chronic respiratory diseases has not been studied.

#### Validity of the ESWT

There have been no studies describing the validity of the ESWT compared with laboratory-based exercise tests within the search timeframe. No studies have reported on the relationship with ESWT and other clinical outcomes. One study in COPD has reported that FEV<sub>1</sub> is an independent predictor of ESWT time; however, it did not correlate with either muscle strength or mass [214].

#### Technical factors affecting ESWT performance

No data were available for differences that might be associated with different operators or the impact of encouragement. Both supplemental oxygen or heliox and oxygen may have an impact on ESWT performance [219, 233, 241, 242]. The studies reflect a difference in conduct, regarding whether the cylinder was carried by the participant or the operator. The changes in performance with oxygen compared with air range from 70 to 174 s [219, 242] or 32–76% of walking time [241]. An additional study reported large improvements in ESWT distance with application of supplemental oxygen (mean increase 275 m, 95% CI 197–352 m) [243]. However, all participants were known oxygen “responders” (increase in ESWT of  $\geq 10\%$  with oxygen), the oxygen cylinder was carried by the operator and the study was not blinded. As

a result, this degree of increase in ESWT performance with oxygen should not be inferred in all patients with COPD.

#### *Relationship of ESWT to clinical outcomes*

There were no studies that evaluated the association of the ESWT and survival or hospitalisation.

#### *Measurements and reporting for ESWT*

There have been no reports of adverse events associated with performing the ESWT in clinical practice or in the context of clinical trials.

The ESWT, like all tests of endurance capacity, should be reported as time (in seconds). Additional measures can be recorded. Three studies demonstrated the potential for the use of  $S_{pO_2}$  to record exertional desaturation during ESWT, either breathing air or for assessment of ambulatory oxygen [219, 233, 242]. One study reported greater desaturation with ESWT compared with 6MWT [233]. No study reported the utility of HR measurement.

#### *Reference equations for ESWT*

No reference equations have been published for the ESWT.

#### *Identifying meaningful change in the ESWT*

Minimal important difference of the ESWT

One study aimed to determine the MID for the ESWT in patients receiving pulmonary rehabilitation ( $n=132$ , mean  $\pm$  SD FEV<sub>1</sub>  $48 \pm 22\%$  predicted, baseline ISWT distance  $203 \pm 129$  m) or bronchodilation ( $n=69$ , FEV<sub>1</sub>  $50 \pm 12\%$  predicted, baseline ISWT distance  $483 \pm 148$  m) [104]. A valid MID estimate could not be obtained from the pulmonary rehabilitation data. Using an anchor-based method, the bronchodilation data indicated that a change of 65 s (95% CI 45–85 s) or 85 m (95% CI 60–115 m) was likely to be perceivable to patients.

#### *Responsiveness of the ESWT*

Seven studies were specifically designed to examine the responsiveness of the ESWT to bronchodilation [105–107], oxygen therapy [219, 233] and pulmonary rehabilitation [232, 234]. The responsiveness of the ESWT was moderate to high, with standardised response means (mean change/standard deviation of change) ranging from 0.52 to 1.27.

## **Discussion**

Studies included in this review consistently showed that the 6MWD is a highly reliable measure in people with chronic lung disease (table S2). In people with COPD, there is an average improvement of 26 m between the first and second tests (table 1). The confidence interval around this estimate is narrow [8] and the estimate is unlikely to be altered substantially by future studies. This learning effect is large enough to be clinically important when the 6MWT is used to evaluate response to treatment or change over time, as failure to consider the learning effect may lead to erroneous interpretation of changes in 6MWD. As a result, consideration should be given to performing two 6MWTs where the test is being used to evaluate longitudinal changes.

This systematic review has demonstrated construct and criterion validity for the 6MWT in patients with chronic respiratory disease. Relationships are strongest with measures of maximal exercise performance and physical activity (tables 2 and 4), indicating that the test is primarily a test of physical capacity. However, the proportion of variance explained is modest, suggesting that these measures are not interchangeable. The 6MWT has historically been considered to be a test of submaximal exercise capacity [2]; however, direct comparisons of the physiological demands of the 6MWT and CPET reveal that, in patients with chronic respiratory disease, measures of peak exercise performance are similar between the tests. Nevertheless, the 6MWT has lower ventilatory requirements (table 3). This body of evidence lends support to the conceptualisation of the 6MWT as a test of functional exercise capacity.

The 6MWD has a clear association with clinical outcomes across a range of chronic respiratory diseases, with the majority of studies identified reporting statistically significant associations of 6MWD with mortality and/or hospitalisation (tables S23–S26 and fig. 1). It is possible that some studies, where 6MWD was not statistically significantly associated with mortality or hospitalisation, were not published. Thus, we cannot exclude some publication bias and the possibility that our summary of the evidence overestimates the strength of association of 6MWD with mortality and/or hospitalisation. Also, it was beyond the scope of this document to identify thresholds for 6MWD to categorise patients according to their risk for the

outcomes. The studies included here addressed the question of the presence and absence of an association of 6MWD with mortality and hospitalisation, rather than finding optimal cut-offs for assessing prognosis.

We identified 17 reference equations for 6MWD, giving rise to wide variation in predicted walk distance. The factors contributing to this variation are likely to include methodological variations as well as local differences in test performance. As a result of this variation, reference equations generated in a local population, using a protocol which closely resembles that used when the reference equations were generated, should be applied where possible. When assessing change in 6MWD, the distance in metres should be used. As well as allowing assessment of meaningful change, this approach also allows the 6MWD to be used in estimation of prognosis in patients with clinically important respiratory disease.

Since the last ATS statement on the 6MWT published in 2002, there have been a number of new publications on the MID for the 6MWD (fig. 2). Encouragingly, recent papers have produced similar estimates, in the range 25–35 m, regardless of the methodology used. The strengths of the current evidence are that they come from a wide variety of clinical sites involving over 5600 participants with moderate to severe chronic respiratory disease and both anchor-based and distribution-based methods were used to estimate the MID. A limitation is the relatively narrowly distributed range of age and 6MWD, which may limit the applicability of the MID estimates to younger adult patients with moderate to severe lung disease. Another limitation is the lack of anchors that correlate strongly with 6MWD, so that even anchor-based estimates need to be interpreted with caution.

It is difficult to investigate whether the MID for 6MWT varies according to disease severity or other patient characteristics, because stratifying patients leads to smaller standard deviations and because correlations of changes in 6MWD with potential anchors often become too small to justify an anchor-based approach. One study reported a MID of 14% of baseline; however, this was less sensitive than the MID in metres [84]. On the basis of current data, a MID based on the absolute change in metres should be used. There is currently little evidence to suggest that the MID varies according to patient characteristics, including the type of chronic respiratory disease.

The relatively recent development of the ISWT and ESWT is reflected by the smaller number of studies identified in our search, in comparison with the number studying 6MWT. The available data indicated that both tests are valid, reliable and responsive (tables 7–11). Most research to date has focused on the use of the ISWT and ESWT in COPD, with more studies needed in other chronic respiratory conditions. There are few studies that have investigated the relationship of ISWT or ESWT to clinical outcomes, relationships that would reinforce the clinical importance of these measures. However, the small number of existing studies has shown that the ISWT is a significant predictor of survival and re-admission [220, 222, 223]. There was little information about the effects of methodological variations on performance of the ISWT and ESWT, probably because these tests are externally paced and performed in accordance with very stringent protocols. This should be considered to be a strength of these tests. Further data are required for reference values of the ISWT, to ensure that suitable equations are available for a wider proportion of the global community.

The measurement properties of the field tests outlined in this review indicate that all are suitable for use in patients with chronic respiratory disease. The choice of an individual test may depend on the circumstances and purpose of the test. For instance, the 6MWD shows strong associations with important long-term outcomes (fig. 1), so may be useful in circumstances where disease staging or estimation of prognosis is required. The availability of consistent MID estimates to which longitudinal change can be compared is also an advantage of this test (fig. 2). However, the shuttle tests may be more sensitive to the effects of common interventions, including bronchodilators [106, 233, 234]. The externally paced nature of the ISWT and ESWT may be an advantage in circumstances where methodological variation is a concern (e.g. multiple sites or operators). Finally, where the larger space requirements of the 6MWT preclude its use, the ISWT and ESWT may be useful alternatives.

The strengths of this review include the extensive body of evidence that was evaluated in a systematic fashion. Both the 6MWT and the shuttle tests were included, allowing comparison of the measurement properties and utility of these different field tests. Limitations include the restriction of the search to the year 2000 onwards, which presents the possibility that earlier, pertinent literature was not included, and the consideration of papers only where there was an abstract published in English. The scope of the review was carefully restricted to adults with respiratory disease; the measurement properties described here cannot be assumed to apply to other populations with chronic disease, or to children.

In conclusion, this systematic review has found robust evidence to support the reliability, validity and responsiveness of the 6MWT, ISWT and ESWT in people with chronic respiratory disease. There is a substantial body of evidence that supports the conceptualisation of the 6MWT as a test of functional exercise capacity for individuals with a range of chronic respiratory conditions. While studies examining the



ISWT and ESWT are more limited in number, the strong measurement properties of these tests are already emerging, particularly with regard to responsiveness to common interventions. There is a sufficient body of evidence to support the use of the 6MWT, ISWT and ESWT in research and in clinical practice for adults with chronic respiratory diseases.

### Acknowledgements

The authors' affiliations are as follows. Sally J. Singh: Centre for Exercise and Rehabilitation Science, University Hospitals of Leicester NHS Trust, Leicester, UK; Milo A. Puhan: Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland; Vasileios Andrianopoulos: Dept of Research and Education, CIRO+ Centre of Expertise for Chronic Organ Failure, Horn, The Netherlands; Nidia A. Hernandez and Fabio Pitta: Laboratory of Research in Respiratory Physiotherapy, Dept of Physiotherapy, Universidade Estadual de Londrina, Londrina, Brazil; Katy E. Mitchell: Centre for Exercise and Rehabilitation Science, University Hospitals of Leicester NHS Trust, Leicester, UK; Catherine J. Hill: Institute for Breathing and Sleep, Austin Health, Melbourne, Australia, and Dept of Physiotherapy, Austin Health, Melbourne, Australia; Annemarie L. Lee: Dept of Physiotherapy, Alfred Health, Melbourne, Australia, and Institute for Breathing and Sleep, Austin Health, Melbourne, Australia; Carlos Augusto Camillo and Thierry Troosters: Faculty of Kinesiology and Rehabilitation Sciences, Dept of Rehabilitation Sciences, Katholieke Universiteit Leuven, Leuven, Belgium; Martijn A. Spruit: Dept of Research and Education, CIRO+ Centre of Expertise for Chronic Organ Failure, Horn, The Netherlands, and REVAL – Rehabilitation Research Center, BIOMED – Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium; Brian W. Carlin: Drexel University School of Medicine, Pittsburgh, PA, USA, and Sleep Medicine and Lung Health Consultants, Pittsburgh, PA, USA; Jack Wanger: ATS Proficiency Standards for Pulmonary Function Laboratories Committee, Rochester, MN, USA; Véronique Pepin: Axe maladies chroniques, Centre de recherche de l'Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, and Dept of Exercise Science, Faculty of Arts and Science, Concordia University, Montreal, QC, Canada; Didier Saey: Centre de recherche, Institut Universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada, and Faculté de médecine, Université Laval, Québec, QC, Canada; David A. Kaminsky: University of Vermont College of Medicine, Burlington, VT, USA; Meredith C. McCormack: Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore, MD, USA; Neil MacIntyre: Duke University, Durham, NC, USA; Bruce H. Culver: Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA; Frank C. Scirba: University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Susan M. Revill: Clinical Diagnostix Ltd, Derby, UK; Veronica Delafosse: Health Sciences Library, Caulfield Hospital, Alfred Health, Caulfield, Australia; Anne E. Holland: Dept of Physiotherapy, La Trobe University, Melbourne, Australia, Dept of Physiotherapy, Alfred Health, Melbourne, Australia, and Institute for Breathing and Sleep, Austin Health, Melbourne, Australia.

### References

- Holland AE, Spruit MA, Troosters T, *et al.* An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J* 2014; 44: 1428–1446.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166: 111–117.
- Guyatt GH, Pugsley SO, Sullivan MJ, *et al.* Effect of encouragement on walking test performance. *Thorax* 1984; 39: 818–822.
- Leach RM, Davidson AC, Chinn S, *et al.* Portable liquid oxygen and exercise ability in severe respiratory disability. *Thorax* 1992; 47: 781–789.
- Cahalin L, Pappagianopoulos P, Prevost S, *et al.* The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. *Chest* 1995; 108: 452–459.
- Scirba F, Criner GJ, Lee SM, *et al.* Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. *Am J Respir Crit Care Med* 2003; 167: 1522–1527.
- Eiser N, Willsher D, Doré CJ. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. *Respir Med* 2003; 97: 407–414.
- Hernandes NA, Wouters EF, Meijer K, *et al.* Reproducibility of 6-minute walking test in patients with COPD. *Eur Respir J* 2011; 38: 261–267.
- Guyatt GH, Thompson PJ, Berman LB, *et al.* How should we measure function in patients with chronic heart and lung disease? *J Chronic Dis* 1985; 38: 517–524.
- Iriberrri M, Gáldiz JB, Gorostiza A, *et al.* Comparison of the distances covered during 3 and 6 min walking test. *Respir Med* 2002; 96: 812–816.
- Kozu R, Jenkins S, Senjyu H, *et al.* Peak power estimated from 6-minute walk distance in Asian patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. *Respirology* 2010; 15: 706–713.
- Eaton T, Young P, Milne D, *et al.* Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. *Am J Respir Crit Care Med* 2005; 171: 1150–1157.
- Jenkins S, Cecins NM. Six-minute walk test in pulmonary rehabilitation: do all patients need a practice test? *Respirology* 2010; 15: 1192–1196.
- Jorquera Guillén MA, Salcedo Posadas A, Villa Asensi JR, *et al.* Reproducibilidad del test de la marcha (walking test) en pacientes afectados de fibrosis quística [Reproducibility of the walking test in patients with cystic fibrosis]. *An Esp Pediatr* 1999; 51: 475–478.
- Ziegler B, Rovedder PM, Oliveira CL, *et al.* Repeatability of the 6-minute walk test in adolescents and adults with cystic fibrosis. *Respir Care* 2010; 55: 1020–1025.
- Poulain M, Durand F, Palomba B, *et al.* 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. *Chest* 2003; 123: 1401–1407.
- Rejeski WJ, Foley KO, Woodard CM, *et al.* Evaluating and understanding performance testing in COPD patients. *J Cardiopulm Rehabil* 2000; 20: 79–88.
- Rodrigues SL, Mendes HF, de Assis Viegas CA. Teste de caminhada de seis minutos: estudo do efeito do aprendizado em portadores de doença pulmonar obstrutiva crônica [Six minutes walk test: study of the effect of learning in chronic obstructive pulmonary disease patients]. *J Bras Pneumol* 2004; 30: 121–125.

- 19 Roomi J, Johnson MM, Waters K, *et al.* Respiratory rehabilitation, exercise capacity and quality of life in chronic airways disease in old age. *Age Ageing* 1996; 25: 12–16.
- 20 Stevens D, Elpern E, Sharma K, *et al.* Comparison of hallway and treadmill six-minute walk tests. *Am J Respir Crit Care Med* 1999; 160: 1540–1543.
- 21 Troosters T, Vilaro J, Rabinovich R, *et al.* Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease. *Eur Respir J* 2002; 20: 564–569.
- 22 Spencer LM, Alison JA, McKeough ZJ. Six-minute walk test as an outcome measure: are two six-minute walk tests necessary immediately after pulmonary rehabilitation and at three-month follow-up? *Am J Phys Med Rehabil* 2008; 87: 224–228.
- 23 Buch MH, Denton CP, Furst DE, *et al.* Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. *Ann Rheum Dis* 2007; 66: 169–173.
- 24 Wilsher M, Good N, Hopkins R, *et al.* The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. *Respirology* 2012; 17: 647–652.
- 25 Gulmans VA, van Veldhoven NH, de Meer K, *et al.* The six-minute walking test in children with cystic fibrosis: reliability and validity. *Pediatr Pulmonol* 1996; 22: 85–89.
- 26 Cunha MT, Rozov T, de Oliveira RC, *et al.* Six-minute walk test in children and adolescents with cystic fibrosis. *Pediatr Pulmonol* 2006; 41: 618–622.
- 27 Mandrusiak A, Maurer C, MacDonald J, *et al.* Functional capacity tests in young people with cystic fibrosis. *N Z J Physiother* 2009; 37: 13–16.
- 28 Chatterjee AB, Rissmiller RW, Meade K, *et al.* Reproducibility of the 6-minute walk test for ambulatory oxygen prescription. *Respiration* 2010; 79: 121–127.
- 29 Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982; 14: 377–381.
- 30 Wijkstra PJ, TenVergert EM, van der Mark TW, *et al.* Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. *Thorax* 1994; 49: 468–472.
- 31 Chuang ML, Lin IF, Wasserman K. The body weight-walking distance product as related to lung function, anaerobic threshold and peak  $\dot{V}O_2$  in COPD patients. *Respir Med* 2001; 95: 618–626.
- 32 Oga T, Nishimura K, Tsukino M, *et al.* Relationship between different indices of exercise capacity and clinical measures in patients with chronic obstructive pulmonary disease. *Heart Lung* 2002; 31: 374–381.
- 33 Carter R, Holiday DB, Nwasuruba C, *et al.* 6-minute walk work for assessment of functional capacity in patients with COPD. *Chest* 2003; 123: 1408–1415.
- 34 Satake M, Shioya T, Takahashi H, *et al.* Ventilatory responses to six-minute walk test, incremental shuttle walking test, and cycle ergometer test in patients with chronic obstructive pulmonary disease. *Biomed Res* 2003; 24: 309–316.
- 35 Turner SE, Eastwood PR, Cecins NM, *et al.* Physiologic responses to incremental and self-paced exercise in COPD: a comparison of three tests. *Chest* 2004; 126: 766–773.
- 36 Starobin D, Kramer MR, Yarmolovsky A, *et al.* Assessment of functional capacity in patients with chronic obstructive pulmonary disease: correlation between cardiopulmonary exercise, 6 minute walk and 15 step exercise oximetry test. *Isr Med Assoc J* 2006; 8: 460–463.
- 37 Hill K, Jenkins SC, Cecins N, *et al.* Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil* 2008; 89: 1782–1787.
- 38 Luxton N, Alison JA, Wu J, *et al.* Relationship between field walking tests and incremental cycle ergometry in COPD. *Respirology* 2008; 13: 856–862.
- 39 Díaz O, Morales A, Osses R, *et al.* Prueba de marcha de 6 min y ejercicio maximo en cicloergometro en la enfermedad pulmonar obstructiva cronica, ¿son sus demandas fisiologicas equivalentes? [Six-minute-walk test and maximum exercise test in cycloergometer in chronic obstructive pulmonary disease. Are the physiological demands equivalent?] *Arch Bronconeumol* 2010; 46: 294–301.
- 40 Sillen MJ, Vercoulen JH, van't Hul AJ, *et al.* Inaccuracy of estimating peak work rate from six-minute walk distance in patients with COPD. *COPD* 2012; 9: 281–288.
- 41 Holland A, Knapman L, Brazzale DJ, *et al.* The 6-minute walk test elicits high but submaximal cardiorespiratory responses in interstitial lung disease. *Am J Respir Crit Care Med* 2010; 181: A2968.
- 42 Dale MT, McKeough ZJ, Munoz PA, *et al.* Functional exercise capacity and health-related quality of life in people with asbestos related pleural disease: an observational study. *BMC Pulm Med* 2013; 13: 1.
- 43 Miyamoto S, Nagaya N, Satoh T, *et al.* Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2000; 161: 487–492.
- 44 Deboeck G, Niset G, Vachiere JL, *et al.* Physiological response to the six-minute walk test in pulmonary arterial hypertension. *Eur Respir J* 2005; 26: 667–672.
- 45 Fowler RM, Jenkins SC, Maiorana AJ, *et al.* Measurement properties of the 6-min walk test in individuals with exercise-induced pulmonary arterial hypertension. *Intern Med J* 2011; 41: 679–687.
- 46 Baldi BG, Albuquerque AL, Pimenta SP, *et al.* Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. *Am J Respir Crit Care Med* 2012; 186: 341–348.
- 47 Ross RM, Murthy JN, Wollak ID, *et al.* The six minute walk test accurately estimates mean peak oxygen uptake. *BMC Pulm Med* 2010; 10: 31.
- 48 Hill K, Dolmage TE, Woon L, *et al.* Comparing peak and submaximal cardiorespiratory responses during field walking tests with incremental cycle ergometry in COPD. *Respirology* 2012; 17: 278–284.
- 49 Blanco I, Villaquirán C, Valera JL, *et al.* Consumo maximo de oxigeno durante la prueba de marcha de 6 minutos en la enfermedad pulmonar intersticial difusa y en la hipertension pulmonar [Peak oxygen uptake during the six-minute walk test in diffuse interstitial lung disease and pulmonary hypertension]. *Arch Bronconeumol* 2010; 46: 122–128.
- 50 Mak VH, Bugler JR, Roberts CM, *et al.* Effect of arterial oxygen desaturation on six minute walk distance, perceived effort, and perceived breathlessness in patients with airflow limitation. *Thorax* 1993; 48: 33–38.

- 51 Brown CD, Benditt JO, Sciruba FC, *et al.* Exercise testing in severe emphysema: association with quality of life and lung function. *COPD* 2008; 5: 117–124.
- 52 Brasil Santos D, de Assis Viegas CA. Correlação dos graus de obstrução na DPOC com lactato e teste de caminhada de seis minutos [Correlation of levels of obstruction in COPD with lactate and six-minute walk test]. *Rev Port Pneumol* 2009; 15: 11–25.
- 53 Waatevik M, Johannessen A, Hardie JA, *et al.* Different COPD disease characteristics are related to different outcomes in the 6-minute walk test. *COPD* 2012; 9: 227–234.
- 54 Chen H, Liang BM, Tang YJ, *et al.* Relationship between 6-minute walk test and pulmonary function test in stable chronic obstructive pulmonary disease with different severities. *Chin Med J* 2012; 125: 3053–3058.
- 55 Annegarn J, Spruit MA, Savelberg HH, *et al.* Differences in walking pattern during 6-min walk test between patients with COPD and healthy subjects. *PLoS One* 2012; 7: e37329.
- 56 Hillman CM, Heinecke EL, Hii JW, *et al.* Relationship between body composition, peripheral muscle strength and functional exercise capacity in patients with severe chronic obstructive pulmonary disease. *Intern Med J* 2012; 42: 578–581.
- 57 van Gestel AJ, Kohler M, Steier J, *et al.* Cardiac autonomic function and cardiovascular response to exercise in patients with chronic obstructive pulmonary disease. *COPD* 2012; 9: 160–165.
- 58 Bruyneel M, Jacob V, Sanida C, *et al.* Determinants de la distance parcourue et de la dyspnee lors du test de marche de six minutes chez les patients atteints de BPCO [Determining factors of walking distance during 6-minutes walk test in COPD patients]. *Rev Mal Respir* 2012; 29: 1104–1110.
- 59 Chetta A, Aiello M, Foresi A, *et al.* Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. *Sarcoidosis Vasc Diffuse Lung Dis* 2001; 18: 170–175.
- 60 Garin MC, Highland KB, Silver RM, *et al.* Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. *J Rheumatol* 2009; 36: 330–336.
- 61 Doyle TJ, Washko GR, Fernandez IE, *et al.* Interstitial lung abnormalities and reduced exercise capacity. *Am J Respir Crit Care Med* 2012; 185: 756–762.
- 62 du Bois RM, Weycker D, Albera C, *et al.* Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. *Am J Respir Crit Care Med* 2011; 183: 1231–1237.
- 63 Minai OA, Santacruz JF, Alster JM, *et al.* Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. *Respir Med* 2012; 106: 1613–1621.
- 64 Schoindre Y, Meune C, Dinh-Xuan AT, *et al.* Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. *J Rheumatol* 2009; 36: 1481–1485.
- 65 Deuschle K, Weinert K, Becker MO, *et al.* Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. *Clin Exp Rheumatol* 2011; 29: Suppl. 65, S53–S59.
- 66 Rambod M, Porszasz J, Make BJ, *et al.* Six-minute walk distance predictors, including CT scan measures, in the COPDGene cohort. *Chest* 2012; 141: 867–875.
- 67 Ziegler B, Rovedder PM, Lukrafka JL, *et al.* Capacidade submáxima de exercício em pacientes adolescentes e adultos com fibrose cística [Submaximal exercise capacity in adolescent and adult patients with cystic fibrosis]. *J Bras Pneumol* 2007; 33: 263–269.
- 68 Reesink HJ, van der Plas MN, Verhey NE, *et al.* Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. *J Thorac Cardiovasc Surg* 2007; 133: 510–516.
- 69 Andersen CU, Mellekjaer S, Hilberg O, *et al.* Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test. *Respir Med* 2012; 106: 875–882.
- 70 Cuomo G, Irace R, Frongillo ME, *et al.* Relationship of the 6-min walking test and quality of life. *Rheumatology* 2012; 51: Suppl. 2, ii103.
- 71 Cícero C, Franchi SM, Barreto AC, *et al.* Ausência de estreita associação entre qualidade de vida e capacidade de exercício na hipertensão arterial pulmonar [Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension]. *Arq Bras Cardiol* 2012; 99: 876–885.
- 72 Pitta F, Troosters T, Spruit MA, *et al.* Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005; 171: 972–977.
- 73 Garcia-Río F, Lores V, Mediano O, *et al.* Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. *Am J Respir Crit Care Med* 2009; 180: 506–512.
- 74 Hernandez NA, Teixeira DC, Probst VS, *et al.* Perfil do nível de atividade física na vida diária de pacientes portadores de DPOC no Brasil [Profile of the level of physical activity in the daily lives of patients with COPD in Brazil]. *J Bras Pneumol* 2009; 35: 949–956.
- 75 Hill K, Dolmage TE, Woon L, *et al.* Defining the relationship between average daily energy expenditure and field-based walking tests and aerobic reserve in COPD. *Chest* 2012; 141: 406–412.
- 76 Borges RC, Carvalho CR. Physical activity in daily life in Brazilian COPD patients during and after exacerbation. *COPD* 2012; 9: 596–602.
- 77 Troosters T, Langer D, Vrijns B, *et al.* Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. *Eur Respir J* 2009; 33: 99–106.
- 78 Mainguy V, Provencher S, Maltais F, *et al.* Assessment of daily life physical activities in pulmonary arterial hypertension. *PLoS One* 2011; 6: e27993.
- 79 Pugh ME, Buchowski MS, Robbins IM, *et al.* Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. *Chest* 2012; 142: 1391–1398.
- 80 Langer D, Cebria i Iranzo MA, Burtin C, *et al.* Determinants of physical activity in daily life in candidates for lung transplantation. *Respir Med* 2012; 106: 747–754.
- 81 Wickerson L, Mathur S, Helm D, *et al.* Physical activity profile of lung transplant candidates with interstitial lung disease. *J Cardiopulm Rehabil Prev* 2013; 33: 106–112.
- 82 Villalba WO, Sampaio-Barros PD, Pereira MC, *et al.* Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. *Chest* 2007; 131: 217–222.
- 83 Redelmeier DA, Bayoumi AM, Goldstein RS, *et al.* Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. *Am J Respir Crit Care Med* 1997; 155: 1278–1282.

- 84 Holland AE, Hill CJ, Rasekaba T, *et al.* Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil* 2010; 91: 221–225.
- 85 Holland AE, Hill CJ, Conron M, *et al.* Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. *Respir Med* 2009; 103: 1430–1435.
- 86 de Almeida FG, Victor EG, Rizzo JA. Hallway versus treadmill 6-minute-walk tests in patients with chronic obstructive pulmonary disease. *Respir Care* 2009; 54: 1712–1716.
- 87 Brooks D, Solway S, Weinacht K, *et al.* Comparison between an indoor and an outdoor 6-minute walk test among individuals with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil* 2003; 84: 873–876.
- 88 Bansal V, Hill K, Dolmage TE, *et al.* Modifying track layout from straight to circular has a modest effect on the 6-min walk distance. *Chest* 2008; 133: 1155–1160.
- 89 Beekman E, Mesters I, Hendriks EJ, *et al.* Course length of 30 metres versus 10 metres has a significant influence on six-minute walk distance in patients with COPD: an experimental crossover study. *J Physiother* 2013; 59: 169–176.
- 90 Gupta R, Goldstein R, Brooks D. The acute effects of a rollator in individuals with COPD. *J Cardiopulm Rehabil* 2006; 26: 107–111.
- 91 Honeyman P, Barr P, Stubbing DG. Effect of a walking aid on disability, oxygenation, and breathlessness in patients with chronic airflow limitation. *J Cardiopulm Rehabil* 1996; 16: 63–67.
- 92 Probst VS, Troosters T, Coosemans I, *et al.* Mechanisms of improvement in exercise capacity using a rollator in patients with COPD. *Chest* 2004; 126: 1102–1107.
- 93 Roomi J, Yohannes AM, Connolly MJ. The effect of walking aids on exercise capacity and oxygenation in elderly patients with chronic obstructive pulmonary disease. *Age Ageing* 1998; 27: 703–706.
- 94 Solway S, Brooks D, Lau L, *et al.* The short-term effect of a rollator on functional exercise capacity among individuals with severe COPD. *Chest* 2002; 122: 56–65.
- 95 Vaes AW, Annegarn J, Meijer K, *et al.* The effects of a “new” walking aid on exercise performance in patients with COPD: a randomized crossover trial. *Chest* 2012; 141: 1224–1232.
- 96 Davidson AC, Leach R, George RJ, *et al.* Supplemental oxygen and exercise ability in chronic obstructive airways disease. *Thorax* 1988; 43: 965–971.
- 97 Fujimoto K, Matsuzawa Y, Yamaguchi S, *et al.* Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. *Chest* 2002; 122: 457–463.
- 98 Rooyackers JM, Dekhuijzen PN, Van Herwaarden CL, *et al.* Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. *Eur Respir J* 1997; 10: 1278–1284.
- 99 Jolly EC, Di Boscio V, Aguirre L, *et al.* Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia. *Chest* 2001; 120: 437–443.
- 100 Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness in “pink puffers”. *Lancet* 1981; 1: 907–909.
- 101 McDonald CF, Blyth CM, Lazarus MD, *et al.* Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. *Am J Respir Crit Care Med* 1995; 152: 1616–1619.
- 102 Crisafulli E, Beneventi C, Bortolotti V, *et al.* Energy expenditure at rest and during walking in patients with chronic respiratory failure: a prospective two-phase case-control study. *PLoS One* 2011; 6: e23770.
- 103 Weir NA, Brown AW, Shlobin OA, *et al.* The influence of alternative instruction on 6-min walk test distance. *Chest* 2013; 144: 1900–1905.
- 104 Pepin V, Laviolette L, Brouillard C, *et al.* Significance of changes in endurance shuttle walking performance. *Thorax* 2011; 66: 115–120.
- 105 Pepin V, Saey D, Whittom F, *et al.* Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005; 172: 1517–1522.
- 106 Pepin V, Brodeur J, Lacasse Y, *et al.* Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease. *Thorax* 2007; 62: 291–298.
- 107 Brouillard C, Pepin V, Milot J, *et al.* Endurance shuttle walking test: responsiveness to salmeterol in COPD. *Eur Respir J* 2008; 31: 579–584.
- 108 Oga T, Nishimura K, Tsukino M, *et al.* The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. *Am J Respir Crit Care Med* 2000; 161: 1897–1901.
- 109 Szekely LA, Oelberg DA, Wright C, *et al.* Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. *Chest* 1997; 111: 550–558.
- 110 Bowen JB, Votto JJ, Thrall RS, *et al.* Functional status and survival following pulmonary rehabilitation. *Chest* 2000; 118: 697–703.
- 111 Pinto-Plata VM, Cote C, Cabral H, *et al.* The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. *Eur Respir J* 2004; 23: 28–33.
- 112 Casanova C, Cote CG, Marin JM, *et al.* The 6-min walking distance: long-term follow up in patients with COPD. *Eur Respir J* 2007; 29: 535–540.
- 113 Cote CG, Pinto-Plata V, Kasprzyk K, *et al.* The 6-min walk distance, peak oxygen uptake, and mortality in COPD. *Chest* 2007; 132: 1778–1785.
- 114 Takigawa N, Tada A, Soda R, *et al.* Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. *Respir Med* 2007; 101: 561–567.
- 115 Casanova C, Cote C, Marin JM, *et al.* Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. *Chest* 2008; 134: 746–752.
- 116 Cote CG, Casanova C, Marin JM, *et al.* Validation and comparison of reference equations for the 6-min walk distance test. *Eur Respir J* 2008; 31: 571–578.
- 117 Puhon MA, Garcia-Aymerich J, Frey M, *et al.* Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. *Lancet* 2009; 374: 704–711.
- 118 Enfield K, Gammon S, Floyd J, *et al.* Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. *J Cardiopulm Rehabil Prev* 2010; 30: 195–202.
- 119 de Torres JP, Casanova C, Cote CG, *et al.* Six-minute walking distance in women with COPD. *COPD* 2011; 8: 300–305.
- 120 Spruit MA, Polkey MI, Celli B, *et al.* Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. *J Am Med Dir Assoc* 2012; 13: 291–297.

- 211 Özgür ES, Nayci SA, Özge C, *et al.* An integrated index combined by dynamic hyperinflation and exercise capacity in the prediction of morbidity and mortality in COPD. *Respir Care* 2012; 57: 1452–1459.
- 212 Tertemiz KC, Kömüs N, Ellidokuz H, *et al.* Kronik obstruktif akciğer hastalığında mortalite ve mortaliteyi etkileyen faktörler [Mortality and factors affecting mortality in chronic obstructive pulmonary disease]. *Tuberk Toraks* 2012; 60: 114–122.
- 213 Lama VN, Flaherty KR, Toews GB, *et al.* Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. *Am J Respir Crit Care Med* 2003; 168: 1084–1090.
- 214 Lederer DJ, Arcasoy SM, Wilt JS, *et al.* Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2006; 174: 659–664.
- 215 Lettieri CJ, Nathan SD, Browning RF, *et al.* The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. *Respir Med* 2006; 100: 1734–1741.
- 216 Han MK, Murray S, Fell CD, *et al.* Sex differences in physiological progression of idiopathic pulmonary fibrosis. *Eur Respir J* 2008; 31: 1183–1188.
- 217 Caminati A, Bianchi A, Cassandro R, *et al.* Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. *Respir Med* 2009; 103: 117–123.
- 218 Swigris JJ, Swick J, Wamboldt FS, *et al.* Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. *Chest* 2009; 136: 841–848.
- 219 Holland AE, Hill CJ, Glaspole I, *et al.* Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease. *Respir Med* 2013; 107: 1066–1072.
- 220 Paciocco G, Martinez FJ, Bossone E, *et al.* Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. *Eur Respir J* 2001; 17: 647–652.
- 221 Saouti N, de Man F, Westerhof N, *et al.* Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. *Respir Med* 2009; 103: 1013–1019.
- 222 Lee WT, Peacock AJ, Johnson MK. The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. *Eur Respir J* 2010; 36: 1294–1301.
- 223 Benza RL, Miller DP, Gomberg-Maitland M, *et al.* Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation* 2010; 122: 164–172.
- 224 Minai OA, Gudavalli R, Mummadi S, *et al.* Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 185: 400–408.
- 225 Lee WT, Ling Y, Sheares KK, *et al.* Predicting survival in pulmonary arterial hypertension in the UK. *Eur Respir J* 2012; 40: 604–611.
- 226 Nickel N, Golpon H, Greer M, *et al.* The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J* 2012; 39: 589–596.
- 227 Scholzel BE, Post MC, Thijs Plokker HW, *et al.* Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension. *Lung* 2012; 190: 161–167.
- 228 Budweiser S, Heidtkamp F, Jörres RA, *et al.* Predictive significance of the six-minute walk distance for long-term survival in chronic hypercapnic respiratory failure. *Respiration* 2008; 75: 418–426.
- 229 Martinu T, Babyak MA, O'Connell CF, *et al.* Baseline 6-min walk distance predicts survival in lung transplant candidates. *Am J Transplant* 2008; 8: 1498–1505.
- 230 Tuppin MP, Paratz JD, Chang AT, *et al.* Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. *J Heart Lung Transplant* 2008; 27: 729–734.
- 231 Nathan SD, Shlobin OA, Reese E, *et al.* Prognostic value of the 6 min walk test in bronchiolitis obliterans syndrome. *Respir Med* 2009; 103: 1816–1821.
- 232 Chen S, Wu YT, Lin JJ, *et al.* The correlations of the six-minute walk test and respiratory functions in chronic obstructive pulmonary disease patients with chronic hypercapnia. *J Exp Clin Med* 2012; 4: 47–51.
- 233 Inal-Ince D, Savci S, Coplu L, *et al.* Functional capacity in severe chronic obstructive pulmonary disease. *Saudi Med J* 2005; 26: 84–89.
- 234 Spruit MA, Watkins ML, Edwards LD, *et al.* Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. *Respir Med* 2010; 104: 849–857.
- 235 van Stel HF, Bogaard JM, Rijssenbeek-Nouwens LH, *et al.* Multivariable assessment of the 6-min walking test in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 163: 1567–1571.
- 236 Callens E, Graba S, Gillet-Juvin K, *et al.* Measurement of dynamic hyperinflation after a 6-minute walk test in patients with COPD. *Chest* 2009; 136: 1466–1472.
- 237 Gallego MC, Samaniego J, Alonso J, *et al.* Disnea en la EPOC: relacion de la escala MRC con la disnea inducida en las pruebas de marcha y de ejercicio cardiopulmonar maximo [Dyspnea in COPD: relation to the MRC scale with dyspnea induced by walking and cardiopulmonary stress testing]. *Arch Bronconeumol* 2002; 38: 112–116.
- 238 Ilgin D, Ozalevli S, Karaali HK, *et al.* Gender effect on the use of modified Borg and visual analog scales in the evaluation of dyspnea in chronic obstructive pulmonary disease. *Pak J Med Sci* 2010; 26: 76–81.
- 239 Nishiyama O, Taniguchi H, Kondoh Y, *et al.* Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. *Respir Med* 2007; 101: 833–838.
- 240 Kabitz HJ, Lang F, Walterspacher S, *et al.* Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. *Chest* 2006; 130: 1496–1502.
- 241 Bourbonnais JM, Malaisamy S, Dalal BD, *et al.* Distance saturation product predicts health-related quality of life among sarcoidosis patients. *Health Qual Life Outcomes* 2012; 10: 67.
- 242 Wong R, Sibley KM, Hudani M, *et al.* Characteristics of people with chronic lung disease who rest during the six-minute walk test. *Arch Phys Med Rehabil* 2010; 91: 1765–1769.
- 243 Al-shair K, Kolsum U, Dockry R, *et al.* Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. *Respir Res* 2011; 12: 3.
- 244 Breukink SO, Strijbos JH, Koorn M, *et al.* Relationship between subjective fatigue and physiological variables in patients with chronic obstructive pulmonary disease. *Respir Med* 1998; 92: 676–682.
- 245 Breslin E, van der Schans C, Breukink S, *et al.* Perception of fatigue and quality of life in patients with COPD. *Chest* 1998; 114: 958–964.

- 156 Katsura H, Yamada K, Wakabayashi R, *et al.* The impact of dyspnoea and leg fatigue during exercise on health-related quality of life in patients with COPD. *Respirology* 2005; 10: 485–490.
- 157 Al-Shair K, Kolsum U, Berry P, *et al.* Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. *Thorax* 2009; 64: 950–955.
- 158 Manguiera NM, Viegas IL, Manguiera Mde A, *et al.* Correlação entre parâmetros clínicos e qualidade de vida relacionada à saúde em mulheres com DPOC [Correlation between clinical parameters and health-related quality of life in women with COPD]. *J Bras Pneumol* 2009; 35: 248–255.
- 159 Theander K, Unosson M. Fatigue in patients with chronic obstructive pulmonary disease. *J Adv Nurs* 2004; 45: 172–177.
- 160 Provencher S, Chemla D, Hervé P, *et al.* Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. *Eur Respir J* 2006; 27: 114–120.
- 161 Swigris JJ, Olson AL, Shlobin OA, *et al.* Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Respirology* 2011; 16: 439–445.
- 162 Ramos RP, Arakaki JS, Barbosa P, *et al.* Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. *Am Heart J* 2012; 163: 580–588.
- 163 Jenkins S, Čecins N. Six-minute walk test: observed adverse events and oxygen desaturation in a large cohort of patients with chronic lung disease. *Intern Med J* 2011; 41: 416–422.
- 164 van Gestel AJ, Clarenbach CF, Stöwhas AC, *et al.* Prevalence and prediction of exercise-induced oxygen desaturation in patients with chronic obstructive pulmonary disease. *Respiration* 2012; 84: 353–359.
- 165 Flaherty KR, Andrei AC, Murray S, *et al.* Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. *Am J Respir Crit Care Med* 2006; 174: 803–809.
- 166 Park JH, Jegal Y, Shim TS, *et al.* Hypoxemia and arrhythmia during daily activities and six-minute walk test in fibrotic interstitial lung diseases. *J Korean Med Sci* 2011; 26: 372–378.
- 167 Fiore C, Lee A, McDonald C, *et al.* Should oxyhaemoglobin saturation be monitored continuously during the 6-minute walk test? *Chron Respir Dis* 2011; 8: 181–184.
- 168 Chuang ML, Lin IF, Chen SP. Kinetics of changes in oxyhemoglobin saturation during walking and cycling tests in COPD. *Respir Care* 2014; 59: 353–362.
- 169 Modrykamien AM, Gudavalli R, McCarthy K, *et al.* Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. *Respir Care* 2010; 55: 584–588.
- 170 Alhamad EH, Shaik SA, Idrees MM, *et al.* Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. *BMC Pulm Med* 2010; 10: 42.
- 171 Pimenta SP, Rocha RB, Baldi BG, *et al.* Desaturation–distance ratio: a new concept for a functional assessment of interstitial lung diseases. *Clinics* 2010; 65: 841–846.
- 172 Teixeira PJ, Costa CC, Berton DC, *et al.* O trabalho de caminhada dos seis minutos não se correlaciona com o grau de obstrução do fluxo aéreo em doentes portadores de doença pulmonar obstrutiva crônica [Six-minute walk work is not correlated to the degree of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)]. *Rev Port Pneumol* 2006; 12: 241–254.
- 173 Casanova C, Celli BR, Barria P, *et al.* The 6-min walk distance in healthy subjects: reference standards from seven countries. *Eur Respir J* 2011; 37: 150–156.
- 174 Dourado VZ, Vidotto MC, Guerra RL. Equações de referência para os testes de caminhada de campo em adultos saudáveis [Reference equations for the performance of healthy adults on field walking tests]. *J Bras Pneumol* 2011; 37: 607–614.
- 175 Hill K, Wickerson LM, Woon LJ, *et al.* The 6-min walk test: responses in healthy Canadians aged 45 to 85 years. *Appl Physiol Nutr Metab* 2011; 36: 643–649.
- 176 Soares MR, Pereira CA. Teste de caminhada de seis minutos: valores de referência para adultos saudáveis no Brasil [Six-minute walk test: reference values for healthy adults in Brazil]. *J Bras Pneumol* 2011; 37: 576–583.
- 177 Osses AR, Yanez VJ, Barria PP, *et al.* Prueba de caminata en seis minutos en sujetos chilenos sanos de 20 a 80 años [Reference values for the 6-minutes walking test in healthy subjects 20–80 years old]. *Rev Med Chil* 2010; 138: 1124–1130.
- 178 Alameri H, Al-Majed S, Al-Howaikan A. Six-min walk test in a healthy adult Arab population. *Respir Med* 2009; 103: 1041–1046.
- 179 Ben Saad H, Prefaut C, Tabka Z, *et al.* 6-minute walk distance in healthy North Africans older than 40 years: influence of parity. *Respir Med* 2009; 103: 74–84.
- 180 Iwama AM, Andrade GN, Shima P, *et al.* The six-minute walk test and body weight-walk distance product in healthy Brazilian subjects. *Braz J Med Biol Res* 2009; 42: 1080–1085.
- 181 Jenkins S, Čecins N, Camarri B, *et al.* Regression equations to predict 6-minute walk distance in middle-aged and elderly adults. *Physiother Theory Pract* 2009; 25: 516–522.
- 182 Masmoudi K, Aouicha MS, Fki H, *et al.* Le test de marche de six minutes: quelles valeurs predictives a appliquer pour les sujets ages entre 40 et 80 ans de la population Tunisienne? [The six minute walk test: which predictive values to apply for Tunisian subjects aged between 40 and 80 years?] *Tunis Med* 2008; 86: 20–26.
- 183 Camarri B, Eastwood PR, Čecins NM, *et al.* Six minute walk distance in healthy subjects aged 55–75 years. *Respir Med* 2006; 100: 658–665.
- 184 Chetta A, Zanini A, Pisi G, *et al.* Reference values for the 6-min walk test in healthy subjects 20–50 years old. *Respir Med* 2006; 100: 1573–1578.
- 185 Poh H, Eastwood PR, Čecins NM, *et al.* Six-minute walk distance in healthy Singaporean adults cannot be predicted using reference equations derived from Caucasian populations. *Respirology* 2006; 11: 211–216.
- 186 Gibbons WJ, Fruchter N, Sloan S, *et al.* Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. *J Cardiopulm Rehabil* 2001; 21: 87–93.
- 187 Enright PL, McBurnie MA, Bittner V, *et al.* The 6-min walk test: a quick measure of functional status in elderly adults. *Chest* 2003; 123: 387–398.
- 188 Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. *Eur Respir J* 1999; 14: 270–274.

- 189 Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. *Am J Respir Crit Care Med* 1998; 158: 1384–1387.
- 190 Teramoto S, Kume H, Ishii T, *et al.* Reference values for 6-min walk distance in Asian adults may not be different from that of Caucasian adults. *Respirology* 2006; 11: 669–670.
- 191 Dourado VZ. Equações de referência para o teste de caminhada de seis minutos em indivíduos saudáveis [Reference equations for the 6-minute walk test in healthy individuals]. *Arq Bras Cardiol* 2011; 96: e128–e138.
- 192 Wise RA, Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. *COPD* 2005; 2: 125–129.
- 193 Puhan MA, Mador MJ, Held U, *et al.* Interpretation of treatment changes in 6-minute walk distance in patients with COPD. *Eur Respir J* 2008; 32: 637–643.
- 194 Puhan MA, Chandra D, Mosenifar Z, *et al.* The minimal important difference of exercise tests in severe COPD. *Eur Respir J* 2011; 37: 784–790.
- 195 Polkey MI, Spruit MA, Edwards LD, *et al.* Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. *Am J Respir Crit Care Med* 2013; 187: 382–386.
- 196 Swigris JJ, Wamboldt FS, Behr J, *et al.* The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. *Thorax* 2010; 65: 173–177.
- 197 Gilbert C, Brown MC, Cappelleri JC, *et al.* Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. *Chest* 2009; 135: 137–142.
- 198 Mathai SC, Puhan MA, Lam D, *et al.* The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 186: 428–433.
- 199 Lacasse Y, Goldstein R, Lasserson TJ, *et al.* Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006; 4: CD003793.
- 200 Puhan M, Scharplatz M, Troosters T, *et al.* Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2009; 1: CD005305.
- 201 Holland A, Hill C. Physical training for interstitial lung disease. *Cochrane Database Syst Rev* 2008; 4: CD006322.
- 202 Liu C, Chen J, Gao Y, *et al.* Endothelin receptor antagonists for pulmonary arterial hypertension. *Cochrane Database Syst Rev* 2009; 3: CD004434.
- 203 Singh SJ, Morgan MD, Scott S, *et al.* Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992; 47: 1019–1024.
- 204 Arnardóttir RH, Emtner M, Hedenström H, *et al.* Peak exercise capacity estimated from incremental shuttle walking test in patients with COPD: a methodological study. *Respir Res* 2006; 7: 127.
- 205 Campo LA, Chilingaryan G, Berg K, *et al.* Validity and reliability of the modified shuttle walk test in patients with chronic obstructive pulmonary disease. *Arch Phys Med Rehabil* 2006; 87: 918–922.
- 206 Dyer CA, Singh SJ, Stockley RA, *et al.* The incremental shuttle walking test in elderly people with chronic airflow limitation. *Thorax* 2002; 57: 34–38.
- 207 Dyer F, Marriner P, Cheema K, *et al.* Is a practice incremental shuttle walk test really necessary? *Chron Respir Dis* 2011; 8: 201–205.
- 208 McKeough ZJ, Leung RW, Alison JA. Shuttle walk tests as outcome measures: are two incremental shuttle walk tests and two endurance shuttle walk tests necessary? *Am J Phys Med Rehabil* 2011; 90: 35–39.
- 209 Zainuldin R, Mackey MG, Alison JA. Prescription of walking exercise intensity from the incremental shuttle walk test in people with chronic obstructive pulmonary disease. *Am J Phys Med Rehabil* 2012; 91: 592–600.
- 210 Onorati P, Antonucci R, Valli G, *et al.* Non-invasive evaluation of gas exchange during a shuttle walking test vs a 6-min walking test to assess exercise tolerance in COPD patients. *Eur J Appl Physiol* 2003; 89: 331–336.
- 211 Palange P, Forte S, Onorati P, *et al.* Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. *J Appl Physiol* 2000; 88: 1715–1720.
- 212 Win T, Jackson A, Groves AM, *et al.* Relationship of shuttle walk test and lung cancer surgical outcome. *Eur J Cardiothorac Surg* 2004; 26: 1216–1219.
- 213 Evans RA, Singh SJ, Collier R, *et al.* Pulmonary rehabilitation is successful for COPD irrespective of MRC dyspnoea grade. *Respir Med* 2009; 103: 1070–1075.
- 214 Steiner MC, Singh SJ, Morgan MD. The contribution of peripheral muscle function to shuttle walking performance in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil* 2005; 25: 43–49.
- 215 England R, Maddocks M, Manderson C, *et al.* Factors influencing exercise performance in thoracic cancer. *Respir Med* 2012; 106: 294–299.
- 216 Dyer CA, Harris ND, Jenkin E, *et al.* Activity levels after pulmonary rehabilitation – what really happens? *Physiotherapy* 2013; 99: 228–232.
- 217 Zwerink M, van der Palen J, van der Valk P, *et al.* Relationship between daily physical activity and exercise capacity in patients with COPD. *Respir Med* 2013; 107: 242–248.
- 218 Sewell L, Singh SJ, Williams JE, *et al.* Seasonal variations affect physical activity and pulmonary rehabilitation outcomes. *J Cardiopulm Rehabil Prev* 2010; 30: 329–333.
- 219 Sandland CJ, Morgan MD, Singh SJ. Detecting oxygen desaturation in patients with COPD: incremental *versus* endurance shuttle walking. *Respir Med* 2008; 102: 1148–1152.
- 220 Emtner MI, Arnardóttir HR, Hallin R, *et al.* Walking distance is a predictor of exacerbations in patients with chronic obstructive pulmonary disease. *Respir Med* 2007; 101: 1037–1040.
- 221 Ketchell RI, Roughton M, Agent P, *et al.* Predicting survival in end-stage cystic fibrosis. *Respir Med* 2009; 103: 1441–1447.
- 222 Ringbaek T, Martinez G, Brøndum E, *et al.* Shuttle walking test as predictor of survival in chronic obstructive pulmonary disease patients enrolled in a rehabilitation program. *J Cardiopulm Rehabil Prev* 2010; 30: 409–414.
- 223 Williams JE, Green RH, Warrington V, *et al.* Development of the i-BODE: validation of the incremental shuttle walking test within the BODE index. *Respir Med* 2012; 106: 390–396.
- 224 Jolly K, Taylor RS, Lip GY, *et al.* Reproducibility and safety of the incremental shuttle walking test for cardiac rehabilitation. *Int J Cardiol* 2008; 125: 144–145.
- 225 Lewko A, Marshall J, Garrod R. Ambulatory oxygen therapy assessment: a comparative study of incremental shuttle and 6-minute walking tests. *Physiotherapy* 2007; 93: 261–266.

- 226 Pilat C, Cossalter B, Rodriguez P, *et al.* Étude comparative du test de marche de six minutes, du test de la navette et de l'épreuve maximale sur cycloergomètre [Comparative study of the 6-minute walking test, the back-and-forth test, and the maximal test on an ergometric bicycle]. *Kinesither Rev* 2005; 5: 33–40.
- 227 Jürgensen SP, Antunes LC, Tanni SE, *et al.* The incremental shuttle walk test in older Brazilian adults. *Respiration* 2011; 81: 223–228.
- 228 Probst VS, Hernandez NA, Teixeira DC, *et al.* Reference values for the incremental shuttle walking test. *Respir Med* 2012; 106: 243–248.
- 229 Harrison SL, Greening NJ, Houchen L, *et al.* Reference values for the incremental shuttle walking test in a healthy population. *Thorax* 2011; 66: Suppl. 4, A55–A56.
- 230 Singh SJ, Jones PW, Evans R, *et al.* Minimum clinically important improvement for the incremental shuttle walking test. *Thorax* 2008; 63: 775–777.
- 231 Dodd JW, Hogg L, Nolan J, *et al.* The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. *Thorax* 2011; 66: 425–429.
- 232 Leung RW, Alison JA, McKeough ZJ, *et al.* Ground walk training improves functional exercise capacity more than cycle training in people with chronic obstructive pulmonary disease (COPD): a randomised trial. *J Physiother* 2010; 56: 105–112.
- 233 Revill SM, Noor MZ, Butcher G, *et al.* The endurance shuttle walk test: an alternative to the six-minute walk test for the assessment of ambulatory oxygen. *Chron Respir Dis* 2010; 7: 239–245.
- 234 Eaton T, Young P, Nicol K, *et al.* The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for COPD patients. *Chron Respir Dis* 2006; 3: 3–9.
- 235 Puhan MA, Scharplatz M, Troosters T, *et al.* Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review. *Respir Res* 2005; 6: 54.
- 236 Puhan MA, Gimeno-Santos E, Scharplatz M, *et al.* Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2011; 10: CD005305.
- 237 Revill SM, Morgan MD, Singh SJ, *et al.* The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. *Thorax* 1999; 54: 213–222.
- 238 Singh SJ, Morgan MD, Hardman AE, *et al.* Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. *Eur Respir J* 1994; 7: 2016–2020.
- 239 Hill K, Dolmage TE, Woon L, *et al.* A simple method to derive speed for the endurance shuttle walk test. *Respir Med* 2012; 106: 1665–1670.
- 240 Revill SM, Williams J, Sewell L, *et al.* Within-day repeatability of the endurance shuttle walk test. *Physiotherapy* 2009; 95: 140–143.
- 241 Laude EA, Duffy NC, Baveystock C, *et al.* The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. *Am J Respir Crit Care Med* 2006; 173: 865–870.
- 242 Revill SM, Singh SJ, Morgan MD. Randomized controlled trial of ambulatory oxygen and an ambulatory ventilator on endurance exercise in COPD. *Respir Med* 2000; 94: 778–783.
- 243 Dyer F, Callaghan J, Cheema K, *et al.* Ambulatory oxygen improves the effectiveness of pulmonary rehabilitation in selected patients with chronic obstructive pulmonary disease. *Chron Respir Dis* 2012; 9: 83–91.